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Glucagon-like peptide-1 (GLP-1) is encoded by the preproglucagon gene (Gcg) and 
expressed in the intestine, pancreas, and central nervous system (CNS). Activation of 
GLP-1 receptors (GLP-1R) on pancreatic β-cells induces insulin secretion in a glucose-
dependent manner while activation of CNS GLP-1Rs suppress feeding. Thus, Gcg-
derived peptides play an important role in gluco- and body weight regulation, and GLP-1 
has been implicated in the success of bariatric surgery. GLP-1 agonists are an effective 
treatment of type 2 diabetes mellitus (T2DM) and obesity. The predominant source of 
circulating GLP-1 is the intestine, but the α-cell becomes an important source when the 
islet is metabolically stressed. Further, plasma GLP-1 is increased in T2DM patients in 
response to inflammation. Nutrient-stimulated GLP-1 functions as an incretin, however, 
the function of GLP-1 during inflammation is unknown. My dissertation proposes that 
during inflammation, GLP-1 plays a metabolic role, functioning to regulate glucose 
levels and food intake, and an immunologic role, functioning to regulate inflammation.  
I examined the metabolic and immunologic role of Gcg under inflammatory conditions. 
Using a combination of high-fat diet (HFD)-induced obesity and a mouse model of 
tissue-specific Gcg expression, I explored the function of GLP-1 in response to 
inflammation by administering lipopolysaccharide (LPS), a well-established tool for 
inducing inflammation. LPS is a known anorectic agent that also alters glucose 
homeostasis; both functions of GLP-1.  
I hypothesized that HFD would exacerbate physiological responses to LPS including 
increased plasma GLP-1, decreased blood glucose levels, and increased sickness-
induced anorexia, as well as systemic inflammatory responses including increased 
plasma cytokines. Indeed, HFD did increase plasma pro-inflammatory cytokines, and 
GLP-1 levels in response to LPS and this was associated with greater anorexia in HFD-
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fed animals. In the next set of studies, I tested whether GLP-1 secreted from either the 
pancreas or intestine was directly regulating feeding and glucose responses to LPS. I 
hypothesized that increases in circulating GLP-1, primarily from the pancreas, were 
necessary for feeding and glucose responses to LPS. I found that while both pancreatic 
and intestinal Gcg contribute to circulating levels of GLP-1 after LPS, the availability of 
either source of GLP-1 had no impact on glucoregulatory or feeding responses. 
Because pancreatic GLP-1 is the more novel contributor to circulation, I investigated the 
impact of Gcg on pancreatic inflammation. I found that 24h after LPS, whole-body chow-
fed Gcg Null animals had increased macrophage accumulation in the pancreas. I saw a 
similar trend in HFD-fed Gcg Null mice. Using a GLP-1R reporter mouse, I found that 
macrophages isolated from the pancreas, but not the bone marrow, express GLP-1R. 
These data suggest that pancreatic GLP-1 directly regulates local macrophage 
responses to inflammation. I conclude that under severe inflammatory conditions, GLP-
1 plays an immunologic rather than metabolic role in the pancreatic responses to LPS, 
through direct macrophage regulation.  
This dissertation indicates a new role for GLP-1 signaling to pancreatic macrophages in 
response to inflammation. Future studies will explore the impact of this increased 
macrophage accumulation on long-term pancreatic function. In fact, my preliminary data 
demonstrate that IP glucose tolerance was impaired 2 weeks following LPS. This lasting 
impact of inflammation on pancreatic function points to a new use of GLP-1 agonists to 




CHAPTER 1                                                                                                                                
1Glucagon-like peptide-1: Actions and Influence on Pancreatic Hormone Function  
Abstract 
Glucagon-like petptide-1 (GLP-1) was described as an incretin over 30 years ago. GLP-
1 is encoded by the preproglucagon gene (Gcg) which is expressed in the intestine, the 
pancreas, and the central nervous system. GLP-1 activates GLP-1 receptors (GLP-1R) 
on the β-cell to induce insulin secretion in a glucose-dependent manner. GLP-1 also 
inhibits α-cell secretion of glucagon. As few, if any, GLP-1R are expressed on α-cells, 
indirect regulation, via β- or δ-cell products has been thought to be the primary 
mechanism by which GLP-1 inhibits glucagon secretion. However, recent work 
suggests that there is sufficient expression of GLP-1R on α-cells for direct regulation as 
well. Although the predominant source of circulating GLP-1 is the intestine, the α-cell 
becomes a source of GLP-1 when the islet is metabolically stressed. Recent work 
suggests the possibility that this source of GLP-1 is also important in regulating nutrient-
induced insulin secretion in a paracrine fashion. More work is also accumulating 
regarding the role of glucagon, another Gcg-derived protein produced by the α-cell, in 
stimulating insulin secretion by acting on GLP-1R. Altogether, these data clearly 
demonstrate the important role for Gcg-derived peptides in regulating insulin secretion. 
Because of GLP-1’s important role in glucose homeostasis, it has been implicated in the 
success of bariatric surgery and has been successfully targeted for treatment of type 2 
diabetes mellitus. 
 
1 This chapter is a reproduction of the following manuscript: 
Davis EM, Sandoval DA. Glucagon-Like Peptide-1: Actions and Influence on Pancreatic Hormone Function. Compr 




Introduction: History of GLP-1 as an incretin   
After the discovery of insulin and the development of the radioimmunoassay to assess 
plasma insulin levels, a debate ensued over whether glucose was the only stimulus for 
insulin secretion. Spurred on by work demonstrating that glucose removal from the 
blood was more rapid with oral vs. IV glucose in dogs (1), McIntyre et al. found that 
glucose was lower but insulin was higher after isocaloric loads of glucose administered 
into the jejunum vs. intravenously in man (2). Months later, a second study had similar 
findings with oral vs. IV glucose (3). These data in conjunction with multiple reports in 
the 1920’s and 30’s that intestinal mucosa had hypoglycemic properties led the authors 
of both papers to hypothesize that a gut-derived humoral substance contributed to the 
regulation of insulin secretion (Figure 1.1). Yet, it was not until the 1970’s when the first 
“incretin” was discovered. When gastric inhibitory polypeptide (GIP; aka glucose-
dependent insulinotropic peptide) was infused into humans intravenously, insulin 
immunoreactivity increased and glucose tolerance was improved (4). However, while 
gut extracts containing GIP increased insulin secretion, removal of GIP from the 
extracts only blunted the insulin response by 30% suggesting the presence of additional 
incretins (5).  
With the discovery of glucagon and in the pursuit of understanding its form and function, 
two other peptides were found on the same mRNA (6,7). These peptides were 
glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2). At this time the 
biological function of these peptides was unknown but later work demonstrated that 
GLP-1, but not GLP-2, stimulated insulin release in rat islets (8) and when infused in 
humans (9). This latter study found that GIP was less effective at increasing insulin 
levels and concluded that GLP-1 was a physiological incretin in man.  We now know 
that GLP-1 has a wide array of physiological functions, yet its role in the pancreas is still 
the most widely studied. The purpose of this review is to discuss the role and 
mechanisms associated with GLP-1 and GLP-1 receptor (GLP-1R) signaling in 
regulation of pancreatic hormone secretion and consequently glucose homeostasis. 




Regulation of preproglucagon (Gcg) expression 
We now know that preproglucagon (Gcg) is the gene that codes for GLP-1 and it is 
expressed in a specific population of intestinal enteroendocrine cells called L-cells.  Gcg 
is also expressed within pancreatic islet α-cells, and in a distinct set of neurons within 
the nucleus of the solitary tract (NTS) (10,11). Gcg undergoes tissue-specific post-
translational modification by prohormone convertases (PC). In intestinal L-cells and 
neurons of the NTS, a specific isoform of PC, PC1/3, is predominantly expressed and 
yields GLP-1, oxyntomodulin, and GLP-2 as the physiologically relevant products (12–
14). In contrast, the α-cell predominantly expresses another PC isoform, PC2, which 
yields glucagon (15). Gcg codes for other bioactive proteins including the proglucagon 
fragments glicentin, glicentin-related pancreatic polypeptide (GRPP), and major 
proglucagon fragment (MPGF) but the functional significance of these peptides is 
unclear.  
Nutrient status is clearly an important factor in regulating Gcg expression across all 3 
organs for which it is expressed. Re-feeding after fasting (16,17), dietary fibers (17–19), 
long chain fatty triglycerides (16), and peptones (20,21), all increase intestinal Gcg 
expression, and amino acids stimulate α-cell hyperplasia and glucagon secretion (22). 
Interestingly, in vitro work in cell lines suggest that physiological stimuli such as 
peptones act via cyclic adenosine monophosphate (cAMP) response element binding 
protein (CREB) signaling to regulate transcriptional responses of Gcg (23,24). In fact, 
increases in cAMP leads to increases in Gcg expression in both the pancreas and 
intestine (17,25–27). Downstream of cAMP but a pathway that is distinct from protein 
kinase A (PKA), activation of exchange protein activated by cAMP 2 (EPAC) also 
increases Gcg transcription in both α- and L-cells (28,29). In contrast, specific to the L-
cell, Gcg expression has been shown to be downstream of the canonical Wnt signaling 
pathway (a specific signaling transduction pathway), β-catenin and transcription factor 7 
like 2 (TCF7L2) (30). Although the mechanisms are unclear, it is also well established 
that bowel resection or injury causes a large increase in intestinal Gcg expression (31).  
The function is likely related to the increase in GLP-2, which functions as an intestinal 
growth factor (see (32) for review). Distinct regulatory mechanisms for Gcg 
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transcriptional control between tissues is in parallel with the distinct patterns of 
prohormone processing in the major cell types producing Gcg peptides. 
Regulation of intestinal GLP-1 secretion 
Within the intestine, the density of Gcg-expressing cells increases from the proximal to 
distal gut with the expression being highest in the colon (33). L-cells within the intestinal 
epithelium and have apical processes that extend into the gut lumen allowing direct 
access to ingested nutrients (34), and all three macronutrients (carbohydrate, fat, 
protein) individually stimulate GLP-1 secretion (35,36).  
Greater numbers of enteroendocrine cells that express Gcg within the lower intestine 
suggests that postprandial GLP-1 secretion is derived from the ileum and colon. Indeed, 
nutrient infusions directly into the ileum causes significantly greater increases in portal 
vein (the major blood vessel that collects intestinal secretions) concentrations of GLP-1 
(37).  Interestingly, in ex vivo studies from human tissue, the duodenum and ileum but 
not the colon were found to be glucose responsive (38) which is different than what is 
reported in mouse colon (39,40) but are consistent with data where patients that have 
had colon resection have normal GLP-1 responses to glucose (41). An argument has 
been made that duodenal secretion of GLP-1 is responsible for early phase GLP-1 
secretion (42) but no direct link has been found. However, the anatomic distribution of 
the L-cells (highest number in distal gut) and the rapid increase in postprandial 
circulating GLP-1 (43) that occurs before nutrients reach the distal gut (44,45) is 
evidence supportive of neural, endocrine and/or paracrine mechanisms being more 
critical to nutrient-induced increases in circulating GLP-1 (46).  
One possibility is that there are feed forward neural or paracrine signals from the upper 
gut to the ileum that stimulates the release of GLP-1 (47,48). Transection of the gut 
below the duodenum resulted in a delayed GLP-1 response to nutrients compared to 
when the gut is simply ligated, the latter being a procedure which preserves neural 
innervation (49). Further support for neural regulation of GLP-1, bilateral 
subdiaphragmatic vagotomy in conjunction with intestinal transection completely 
abolishes nutrient induced GLP-1 secretion (49). In rodents, human enteroendocrine 
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cells, and in perfused porcine ileum, cholinergic agonists, which bind to receptors in 
both the enteric and parasympathetic nervous system, stimulate GLP-1 secretion 
(26,48,50,51). Conversely, norepinephrine and α-adrenergic agonists inhibit (50) and β-
adrenergic agonists stimulate (52,53) GLP-1 secretion suggesting that sympathetic 
neural innervation of the gut is also important in the regulation of GLP-1 secretion. In 
humans, atropine, which is a parasympathetic nervous system agonist, blunts glucose-
induced increases plasma GLP-1 (45). Together these data lend support to the idea that 
neuronal influences are at play in regulation of postprandial GLP-1 secretion.  
Despite the anatomic limitations, there are several potentially overlapping nutrient-
sensing mechanisms that have been found to regulate intestinal GLP-1 secretion. Both 
passive glucose transport through the sodium glucose cotransporter 1 (SGLT1) (39,54) 
and active glucose transport through glucose transporter 2 (GLUT2) have been found to 
regulate intestinal GLP-1 secretion as inhibitors for each transporter blocks GLP-1 
release (38). Similar to pancreatic β-cells that secrete insulin, potassium adenosine tri-
phosphate (KATP) channels and its associated sulfonylurea receptor are also expressed 
in L-cells (55,56). Data suggest that increased glucose metabolism within L-cells leads 
to an increase in ATP and consequently depolarization of KATP channels triggering GLP-
1 secretion (39,55,57).  Interestingly, GLUT2 is linked to KATP channels (58) while 
SGLT1 is linked to voltage gated sodium and calcium channels in GLP-1 secretion (38). 
However, in animal models pharmacological (59) or genetic (60) blockade of SGLT1 
had a bigger impact on blunting GLP-1 secretion compared to the same manipulations 
towards GLUT2. In contrast, ex vivo studies in human tissue suggests GLUT2 may be 
more important (38). It is unknown whether these differences are simply due to the 
species or the experimental conditions; in particular for the ex vivo experiments.  
Early work demonstrating that PKA activators could stimulate GLP-1 secretion from cell 
lines suggested that G-protein coupled receptors (GPCR) were involved in the 
regulation of GLP-1 secretion (51,61,62). Gαs and Gαq-coupled receptors responding to 
luminal bile acids and long-chain fatty acids have demonstrated potent effects on GLP-1 
secretion (63). Bile acids signaling through the Gαs protein-coupled bile acid receptor 1, 
or TGR5, stimulate GLP-1 secretion (63,64). Bile acids also signal through farnesoid X 
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receptor, a nuclear transcription factor, but TGR5 is the primary bile acid receptor that 
can drive GLP-1 secretion (65). Offering clinical promise, in vitro data using primary 
enteroendocrine cells and an intestinal cell line indicated that pharmacologic TGR5 
agonists are more potent GLP-1 secretagogues and are better at enhancing L-cell 
responses to calcium and glucose-induced GLP-1 secretion compared to naturally 
occurring bile acids (64).  
Long-chain fatty acids and their derivatives specifically activate multiple types of GPCRs 
including, GPR119, GPR120, and GPR40 (66), and this activation also stimulates GLP-
1 secretion. GPR119 is a Gαs-coupled protein receptor and it is highly co-localized to L-
cells within the GI tract. GPR119 agonists increase GLP-1 secretion (67) and GPR119 
knockout mice have a reduced GLP-1 response to an oral glucose load (68). However, 
a randomized double-blind placebo controlled trial revealed that GPR119 agonism was 
not as effective at increasing total and active GLP-1 responses to glucose or a mixed 
liquid meal nor was it as effective at improving glucose control over a 2-week study 
period (69). In contrast to GPR119, a Gαs-coupled receptor, GPR120 and GPR40 are 
Gαq-coupled receptors that signal through protein kinase C. Activation of both GPR40 
and GPR120 result in increased GLP-1 secretion (70–73), however, their role may be 
more pharmacological than physiological. While members of these GPCR families were 
under active investigation as drug targets for the treatment of type 2 diabetes mellitus 
(T2DM), due to lack of efficacy the number of drugs in the pipeline have been drastically 
reduced.  
Another type of GPCR that is expressed in the GI tract and has been found to be linked 
to GLP-1 secretion are “sweet taste receptors” (74). These same receptors are 
expressed in the tongue and are integral in sweet taste perceptions. Their function in 
the GI tract is less clearly understood. Non-nutritive agonists of sweet taste receptors do 
increase GLP-1 levels and mice null for one such sweet taste receptor, α-gustducin, 
have reduced GLP-1 responses to an oral glucose load (74). Some data suggest that 
pharmacological inhibition of sweet taste receptors blunt GLP-1 responses to nutrients 
(75), but other studies found no impact of sweet taste receptor agonists on GLP-1 
secretion in humans (40,76) or in in vivo or ex vivo studies in rats (77).  
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Altogether it seems that many molecular signaling pathways have been linked to GLP-1 
secretion (Figure 1.2), and it is possible that all of these pathways are involved in order 
to provide an integrated response that also allows for fine tuning of GLP-1 secretion. 
One example of this is recent work that found a synergistic action of pharmacological 
TGR5 and GPR40 activation on the electrophysiological properties of L-cells (78). 
However, while data in mouse models are promising, there are currently no therapies 
currently in clinical trials focused on GPCR signaling to increase plasma GLP-1. 
Whether this is because these GPCRs are not important or whether increasing intestinal 
GLP-1 secretion, alone, is sufficient for obesity and/or T2DM treatment remains to be 
determined.  
GLP-1 Receptor distribution and signaling 
Direct regulation of insulin secretion 
The GLP-1R is a GPCR that is expressed within the pancreas, lung, adipose tissue, 
kidney, heart, vascular smooth muscle, and in a number of specific nuclei within the 
CNS (25,79). Most of what we know about GLP-1R signaling is derived from studying 
the β-cell population of GLP-1R. When glucose is transported into the β-cell, its 
metabolism generates ATP which provides energy for closure of KATP channels and 
consequently an increase in intracellular calcium; the latter being necessary for 
exocytosis of insulin. Binding of the GLP-1R produces cAMP and consequently 
activation of PKA and EPAC2 (80) which potentiates glucose-stimulated insulin release 
(80–82). With fasting and when intracellular ADP is increased, PKA activation 
hyperpolarizes the β-cell membrane by increasing KATP channel conductance. When 
ADP levels are reduced with glucose metabolism, PKA phosphorylates a subunit of the 
KATP channel leading to channel closure and depolarization (83). This extends to 
pharmaceutical activation of the GLP-1R in that GLP-1R agonists are weak insulin 
secretagogues at basal glucose levels. Further, the ability of GLP-1 to suppress 
feeding, an action dependent upon CNS receptors, is blunted in fasted conditions 
(84,85) and dependent upon nutrient-dependent intracellular pathways (86) indicating 
that CNS GLP-1R signaling is also dependent upon nutrient availability.  
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Although pharmacological data make it very clear that GLP-1 regulates insulin 
secretion, genetic data suggest that the system is more complex than a simple 
endocrine model of insulin regulation. Genetic models demonstrate that although GLP-1 
regulates insulin secretion through the β-cell GLP-1R (87), the necessity of these 
receptors depend on the route of delivery of nutrients. Mice with an inducible knockout 
of the β-cell GLP-1R have normal oral, but impaired intraperitoneal (IP) glucose 
tolerance (88). This is interesting as even whole body GLP-1R KO mice have greater 
impairments in IP vs. oral glucose tolerance. Importantly, these responses could also be 
explained by the redundancy of insulinotropic signals from the gut or nervous system 
during oral vs. IP glucose loads, but in the end still demonstrate that β-cell GLP-1R, in 
and of themselves, are not necessary for oral glucose tolerance.  
GLP-1R regulation of insulin secretion independent of the β-cell GLP-1R 
If GLP-1 has a role for regulating insulin secretion independent of its β-cell receptor, 
what would the population of receptors be? Given the rapid postprandial increase in 
insulin, one possibility is nervous system GLP-1R. Indeed, direct administration of GLP-
1 into the 3rd cerebral ventricle (ICV) increases insulin secretion (89,90); an effect that is 
maintained in mice fed a high fat diet (91). In both mice and rats, administration of ICV 
exendin-4(9-39) (Ex9), a potent GLP-1R antagonist, during oral glucose impairs glucose 
tolerance and reduces insulin levels (89,92,93).  
There are no detectable GLP-1R on the liver or on skeletal muscle and yet GLP-1 has 
repeatedly been shown to not just increase insulin secretion but also to improve insulin 
sensitivity. Despite the lack of hepatic GLP-1R expression, intravenous GLP-1 inhibits 
hepatic glucose production independent of islet hormones in humans (94). CNS GLP-
1R activation may also explain this finding. When administered directly into the arcuate 
nucleus of rats, GLP-1 decreases hepatic glucose production under clamped conditions 
where glucose and insulin were held constant (89). The specific population of neurons 
responsible for this effect is not clear as  deletion of GLP-1R within the hypothalamus or 
even more specifically on pro-opiomelanocortin neurons with the arcuate nucleus of the 
hypothalamus also do not impact normal glucose regulation (95). GLP-1 activates vagal 
afferent neuronal activity and administration of GLP-1R antagonists into the portal vein 
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impairs glucose tolerance (96) suggesting that the peripheral nervous system is also 
important in mediating GLP-1 effects on glucose homeostasis.  However, neither 
genetic deletion of CNS nor vagal neuronal GLP-1R is not necessary for normal glucose 
regulation (97), but CNS (97) and specifically glutamatergic excitatory (vs. GABAergic 
inhibitory) neurons (98) that express GLP-1R are necessary for the weight-reducing 
effects of liraglutide, a long-acting GLP-1 agonist. Lastly, in obese mice and in humans, 
administration of GLP-1 agonists reduces hepatic steatosis (99–102). Whether these 
effects are also due to CNS activation is unclear but they do seem to be independent of 
the effect of chronic GLP-1 administration to reduce body weight. It remains to be seen 
whether the discrepancy between the genetic vs. pharmacological manipulation of CNS 
GLP-1R signaling and the impact on glucose regulation is due to a species difference or 
a development compensation in the mice. The CNS distribution of the GLP-1R is 
disperse and different populations of receptors have sometimes very different functions 
(see (103) for review). As neuroscience technology becomes more sophisticated, the 
capability to tease this system apart becomes more promising.  
GLP-1R regulation of β-cell mass 
In addition to stimulating insulin secretion, GLP-1R activation benefits β-cell survival and 
importantly does so in the presence of multiple apoptotic conditions including 
hyperglycemia, hyperlipidemia, inflammatory cytokines, and oxidative stress (104). The 
exact signaling mechanisms that drive β-cell growth and differentiation are still being 
resolved. However, phosphatidylinositol 3-kinase (PI3K) rather than PKA activation 
seems to be the principle signaling mechanism by which the GLP-1R controls β-cell 
growth and apoptosis. GLP-1 also induces a rapid cAMP-dependent activation of 
extracellular signaling kinase, ERK1/2, and a delayed β-arrestin (an adaptor protein 
necessary for GLP-1R signaling (105))-dependent increase of ERK1/2 signaling (106). 
Providing a direct link, β-arrestin has been found to be necessary for the anti-apoptotic 
effects of GLP-1 (106) and GLP-1 administration to a β-cell line reduces H2O2-induced 
apoptosis through both cAMP and PI3K (but not ERK1/2) signaling with independent but 
additive effects (107). Liraglutide also protects against apoptosis via PI3K signaling and 
the consequent phosphorylation of AKT (108). Recent work has demonstrated that 
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GLP-1-induced activation of PI3K is through activation of epidermal growth factor 
receptor 1 (EGFR), a tyrosine kinase receptor. EGFR has been found to be necessary 
for the ability of exendin-4 (Ex4), another long-acting GLP-1R agonist, to regulate β-cell 
mass and proliferation (109). Because EGFR directly activates PI3K, these data provide 
a link between GLP-1R signaling, PI3K, and β-cell proliferation. Downstream of AKT 
phosphorylation in the activation of β-cell proliferation is Wnt signaling, a pathway 
established in cancer biology to be critical for cell proliferation and survival. Activation 
AKT leads to accumulation of cytosolic β-catenin and subsequent translocation to the 
nucleus where it forms a complex with TCF7L2 (110), a transcription factor that 
activates expression of Wnt target genes (111). siRNA silencing of β-catenin and a 
dominant negative insertion of TCF7L2 in INS-1 cells (a β-cell line) blunted the ability of 
Ex4 to stimulate β-cell proliferation (110), indicating that Wnt signaling is necessary for 
GLP-1-induced β-cell proliferation.  
These data illustrate the wide-ranging signaling pathways induced by GLP-1R activation 
to regulate β-cell mass and function. There is still much debate about the relevance of 
this impact of GLP-1 signaling in cell lines and in mice vs. in humans. While it was found 
that short-term incretin therapies do not expand β-cell mass in young male mice (112), 
in a model that enables assessment of human β-cell replication in vivo, it was found that 
Ex-4 induced proliferation occurred only in juvenile, but not adult islets (113). This work 
provides an important advance in our understanding of the decline in β-cell proliferation 
that occurs with aging and indicates that even pharmacological GLP-1 signaling may 
not be critical in driving proliferation in humans.  
Impact of GLP-1 on glucagon secretion 
GLP-1-induced inhibition of glucagon secretion has been demonstrated in a variety of 
species including humans (114,115). Activation of the GLP-1R also inhibits glucagon 
release from isolated islets or in perfused pancreas studies (116).  While the data are 
clear that GLP-1 inhibits glucagon, the mechanisms are debated as some report low 
(117,118), if any (99,119), expression of the GLP-1R on α-cells. One possibility is that 
the impact of GLP-1 on glucagon release is indirect through release of glucagon-
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regulating hormones from nearby β- and/or δ-cells (116,120). While somatostatin 
secreted from δ-cells inhibited glucagon secretion, a somatostatin antagonist only 
partially blunted the GLP-1-induced decrease in glucagon (121) suggesting additional 
mechanisms at play. 
GLP-1 also acts on β-cells to secrete insulin which is known to suppress glucagon 
(122). However, co-secreted with insulin are amylin, zinc (Zn2+) and GABA; all of which 
have also been shown to individually suppress the release of glucagon. For example, 
GABA released from β-cells enhances glucose inhibition of glucagon secretion by acting 
via an Akt kinase-dependent pathway (123). Co-secreted with insulin in hyperglycemic 
conditions, Zn2+ has been found to have inhibitory action on glucagon release from α-
cells (124–126) and α-TC6 cells (an α-cell line) (126). The potential role of Zn2+ has 
found increasing interest due to the fact that genome-wide association studies (GWAS) 
have revealed that rare variants of a Zn2+ transporter gene are associated with 
improved glucose homeostasis and protection from T2DM (127). To determine whether 
the impact of Zn2+ was independent of insulin, streptozotocin-treated (to kill β-cells) rats 
where studied during pancreatic perfusion studies (125). In these rats, disruption of the 
intrapancreatic infusion of insulin bound to Zn2+, but not of insulin unbound to Zn2+, 
accelerated glucagon secretion, indicating that Zn2+ but not insulin inhibits glucagon 
secretion. The thinking is that Zn2+ inhibits pyruvate-induced glucagon secretion via 
opening of KATP channels and subsequent inhibition of α-cell electrical activity (128). It is 
important to note that contrasting data exist suggesting that Zn2+ does not regulate 
glucagon (129).  However, given the connection to the GWAS data, at a minimum Zn2+ 
is important for glucose control and a logical link for that is through inhibiting release of 
glucagon.  
In addition to Zn2+, insulin is co-secreted with amylin, and amylin has also been found to 
dose-dependently suppress arginine-mediated glucagon secretion in rats (130) while 
pharmacological inhibition of amylin signaling enhances glucagon secretion (131). 
Pramlintide, an amylin receptor agonist, improves glycemic control in T2DM patients 
and at least part of that effect is via inhibition of postprandial glucagon secretion (132). 
A caveat to all of these studies demonstrating that β-cell products could play an indirect 
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role in GLP-1-mediated regulation of glucagon is that GLP-1 maintains the ability to 
inhibit glucagon secretion in type 1 diabetic patients who have little to no endogenous 
insulin (133,134) demonstrating that GLP-1 inhibition of glucagon secretion does not 
fully depend on β-cell products.  
Besides the low expression levels of the GLP-1R on the α-cell, another caveat to the 
potential direct role of GLP-1 on glucagon regulation is that generally, GLP-1R 
activation generates cAMP and increases in cAMP are associated with increased, 
rather than decreased, glucagon release. Recently, an α-cell GLP-1R KO mouse was 
generated by crossing a loxP flanked humanized GLP-1R mouse with a Gcg-Cre mouse 
(135). Theoretically, this will eliminate the GLP-1R only from α-cells as neither L-cells 
nor Gcg-expressing neurons express the GLP-1R. In these mice, the glucagon 
response to increasing glucose loads was increased rather than decreased in the α-cell 
GLP-1R KO mice. While ad lib fed glucagon levels were higher in the α-cell GLP-1R KO 
mice, a curious finding was that these mice had impaired IP glucose tolerance and 
increased glucagon response to an IP glucose load, a condition that does not stimulate 
gut-derived GLP-1 secretion. Regardless, a couple of studies have provided a basis for 
an evolving story on how GLP-1 might mechanistically inhibit glucagon levels. The idea 
is that there are low numbers of GLP-1R on α-cells but these receptors have enough 
capacity to generate proportionately small amounts of cAMP (117). This small amount 
of cAMP mediates suppressive effects glucagon secretion through discrete inhibition of 
high voltage N-type calcium channels in mice (117) and via P/Q-type voltage-gated 
calcium channels in humans (136). In their hands, GLP-1 retained this inhibitory effect 
with either insulin or somatostatin antagonists onboard (117,136). However, it would be 
interesting to know if somatostatin and insulin signaling are synergistic in the paracrine 
effect; ie. if both antagonists were given, would GLP-1 still inhibit glucagon release. 
Regardless, this model explains how low and high intra-cellular cAMP concentrations 
with the α-cell could have opposing actions on glucagon secretion. Thus, while there is 
much to be learned about the signaling that drives GLP-1-induced inhibition of glucagon 
secretion, there are multiple indirect and direct mechanisms at play. The inhibitor action 
of GLP-1 on glucagon levels is often overlooked in favor of its role as an insulin 
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secretagogue, but it is clear that pharmacologically this is one mechanism by which 
GLP-1R agonists improve glycemia in T2DM patients (137). 
Role of α-cell produced Gcg in insulin secretion 
α-cell GLP-1 during metabolic stress 
PC1/3, which processes GLP-1 (and GLP-2 and oxyntomodulin) from Gcg, is more 
predominantly expressed in the gut and CNS, but α-cell PC1/3 activity and/or 
expression is found in embryonic and neonatal mice, with pregnancy, and in models of 
prediabetes and diabetes (138–141).  Along with this, α-cell GLP-1 clearly increases 
when the pancreas is under metabolic stress (142–144). Although the incretin model 
that intestinally-secreted GLP-1 is the functional source of GLP-1, these data do 
suggest that the α-cell pool of GLP-1 also has a functional role in the pancreas.  
Streptozotocin (STZ), a β-cell toxin, is used to model diabetes in animals. In rats 
administered STZ, there is an acute increase in islet Gcg and PC1/3 expression that 
leads to an increased processing of α-cell Gcg to GLP-1 (141). While the function of α-
cell GLP-1 under metabolic stress conditions is unknown, glucagon receptor (GcgR) KO 
animals have a developmentally driven increase in pancreatic GLP-1 production and 
are also, interestingly, resistant to STZ-induced diabetes (145). Further, blockade of the 
GLP-1R in GcgR deficient mice prevented the improved glucose tolerance seen in the 
mice (146). Additionally, mice with a cre-inducible α-cell KO of PC1/3 (although the 
extent to which intestinal and CNS PC1/3 expression was intact is unknown) had 
reduced levels of GLP-1 in the islet and greater impairments of glucose and insulin in 
response to STZ (144). Altogether these data suggest that α-cell GLP-1 production 
provides a protective effect on β-cell function during times of stress. Further examples 
of this are that in cultured α-cell lines or isolated islets, high media glucose 
concentrations increase PC1/3 expression and cellular GLP-1 content (147,148). α-cell 
hyperplasia also occurs with high fat diet and this precedes β-cell mass expansion 
(149), and in both human and mouse islets there is positive correlation between islet 
levels of GLP-1 and adiposity (150). Together these data suggest a role for α-cell GLP-1 
production in the adaptation to metabolic disease. Whether this increase is as a 
protective factor that eventually fails or a part of the pathophysiology is unknown.  
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Although our focus here is on pancreatic GLP-1, GLP-1 in the circulation, presumably 
due to intestinally-secreted GLP-1, also increases with inflammation and the 
mechanism by which this occurs has been linked to one particular cytokine, interleukin 6 
(IL-6). IL-6 is increased in inflammatory conditions including exercise, and obesity 
(143,149). Under severe inflammatory conditions such as sepsis, or when induced by 
exogenous lipopolysaccharide (LPS) administration, there is a systemic increase in 
GLP-1 that is dependent on IL-6 (151,152). In response to LPS, the increase in GLP-1 
is dose-dependent, and GLP-1 levels remain elevated for 8-hours (151). Whereas in IL-
6 knockout mice, there is no increase in GLP-1 after LPS administration (151). With 90 
min of exercise in mice, there is an acute increase in IL-6 and GLP-1 and again this 
increase in GLP-1 was not seen in IL-6 knockout mice (143). To look at α-cell production 
specifically, IL-6 injections were given twice daily for over a week and the protein 
content of pancreatic GLP-1 and insulin were both increased (143). Despite the 
evidence showing that IL-6 increases GLP-1 secretion from the α-cell, the function, and 
whether it relates to glucose regulation or not, during this kind of inflammatory state is 
unknown. After several hours, LPS treatment causes elevated IL-6 levels and 
hypoglycemia to develop and Ex4 administration blunts this hypoglycemic effect in rats 
suggesting that the effect of GLP-1 is related to glucose control (153) although the 
direction goes opposite of what we normally think of as GLP-1-mediated glucose 
control.  Another leading hypothesis is that IL-6 induced GLP-1 is a part of a negative-
feedback loop to inhibit or restrain inflammatory responses. Rat islets treated with 
liraglutide showed both decreased pro-inflammatory cytokine levels (IL-6 and TNF-α) 
and the islets had improved function (154). Both the glucose and anti-inflammatory 
effect of GLP-1 point to α-cell GLP-1 acting locally rather than centrally. However, 
whether these pharmacological agonists have the same function as endogenously 
secreted GLP-1 from the α-cell remains an important unresolved question.   
Thus, both metabolic (hyperglycemia, STZ-induced, diabetes) and physiological 
(exercise, inflammation) stress conditions influence IL-6 circulating levels which may be 
the factor that triggers GLP-1 secretion from the α-cell (Figure 1.3). However, the role of 
increased GLP-1 secreted from the α-cell under inflammatory conditions, how it impacts 
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overall glucose homeostasis, and how this may be targeted pharmacologically is 
unknown.  
α-cell GLP-1 in normal glucose regulation 
The accepted dogma of GLP-1 secreted from the intestine and acting on the pancreas 
in an endocrine manner is difficult to reconcile given the observations that GLP-1 is 
rapidly degraded by dipeptidylpeptidase 4 (DPP4) and very little, in fact only ~10% of 
intestinally-secreted GLP-1, reaches the circulation (155–157). While the role of α-cell 
secreted GLP-1 became established during states of metabolic stress, the question 
remains whether or not it has a role in normal glucose control. Although controversial, 
pancreatic GLP-1 has been found in normal islets and its expression increases with 
increasing glucose concentrations (144,147,148). In isolated human islets the amount of 
GLP-1 was low under basal conditions and was only present in the cell lysates, not the 
culture medium in one study (148). However, others have found pancreatic GLP-1 to be 
higher in human vs. mouse islets (144). In addition, PC1/3 activity can also be up-
regulated by activating a bile acid receptor (TGR5) known to regulate GLP-1 secretion 
(147). These data suggest that the conditions by which α-cell GLP-1 is assessed may 
be important in the ability to detect GLP-1 levels.  
Recently, the role of pancreatic Gcg, the gene that encodes GLP-1, was explored using 
a Cre lox-P mouse model that selectively reactivated the endogenous Gcg gene in the 
pancreas vs. the intestine while the remaining tissues remained devoid of Gcg (142). To 
understand the role of GLP-1R activation specifically, glucose responses to Ex9, a GLP-
1 receptor antagonist, was examined. Ex9 had no impact on Gcg deficient animals 
indicating that Ex9 was a true GLP-1R antagonist in vivo. This indicates that the 
presence of GLP-1 is necessary for the ability of Ex9 to impair glucose. Interestingly, 
animals that only expressed pancreatic, but not animals that expressed only intestinal 
Gcg had impaired glucose tolerance (whether oral or IP) in response to Ex9. Thus, the 
source of the GLP-1 ligand necessary for the ability of Ex9 to impair glucose tolerance 
was pancreatic and not intestinal GLP-1.  
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However, there is an important caveat to this work. It has been known for quite some 
time that glucagon increases insulin secretion (122) and this was presumed to be 
through glucagon receptors. However, three independent islet perfusion studies 
demonstrated that glucagon increases insulin not by acting on glucagon receptors but 
by acting on GLP-1R (158–160). At a first pass, these data suggest the possibility that it 
was pancreatic glucagon rather than pancreatic GLP-1 that was responsible for the 
ability of Ex9 to impair glucose tolerance in the previous study (142). However, the 
ability of glucagon to bind to the GLP-1R is extraordinarily less potent than GLP-1 (159). 
In addition, it would mean that the entirety of Ex9’s action is by impairing glucagon 
action on β-cell GLP-1R since Ex9 had no impact on glucose tolerance in animals that 
had fully restored intestinal Gcg expression and postprandial circulating GLP-1 levels 
(142). Lastly, experimental conditions that lead to the increase in glucagon and 
glucagon action on the GLP-1R was specific to having both elevations in glucose and 
amino acids. The in vivo experiments described above (142) were only done with oral 
glucose.  
Other mouse models have been derived in attempt to separate the role of α-cell 
glucagon and GLP-1. One used a diphtheria toxin-inducible α-cell KO of Gcg and this 
mouse had a small impairment of age-induced IP glucose tolerance (144). 
Administration of DPP4 inhibitor, but not glucagon, restored glucose tolerance in these 
mice. The authors suggest this provides evidence that intestinally-derived GLP-1 can 
compensate for the lack of α-cell GLP-1. However, DPP4 inhibitors increase bioactive 
GLP-1 AND GIP and previous work demonstrates that these drugs can fully improve 
glucose tolerance even if only one of the incretin’s have intact signaling (161). Isolated 
islets from another mouse model with α-cell KO of PC1/3 had reduced levels of GLP-1 
in the islet and reduced glucose-stimulated insulin secretion (144). These mice also had 
impaired intraperitoneal, but not oral glucose tolerance (144). Similarly, β-cell GLP-1R 
KO mice have normal oral but not intraperitoneal, glucose tolerance (87,162). Thus, a 
model where paracrine, rather than endocrine action of preproglucagon peptides in 
regulating insulin emerges. Because of the nature of preproglucagon processing, it will 
be difficult to distinguish between the impact of α-cell derived glucagon vs. GLP-1 on 
local GLP-1R. However, this work clearly demonstrates that the conventionally accepted 
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role of GLP-1 biology is inadequate. The combined impact factors driving an increase in 
α-cell GLP-1 and glucagon are summarized in Figure 1.4.  
If we ignore the intestinal vs. pancreatic source of GLP-1 topic and just focus on the fact 
that GLP-1 regulates insulin secretion by acting directly on β-cell GLP-1 receptors and 
either directly or indirectly suppresses glucagon then under what circumstance is 
glucagon important for β-cell GLP-1R signaling? Of the components of a mixed meal 
(lipids, carbohydrates, and proteins), free fatty acids, if anything decrease glucagon 
levels in man (163), carbohydrates potently suppress glucagon, and proteins (amino 
acids) potently stimulate glucagon secretion (164). Interestingly, free fatty acids 
suppress the ability of arginine to stimulate glucagon secretion in man (163) suggesting 
that even in a mixed meal situation, increases in glucagon levels are restrained. In 
addition to GLP-1 suppressing glucagon, insulin and somatostatin, which also increase 
during a meal, also suppress glucagon levels. Many questions arise from these 
observations. Is the system set-up to suppress redundant signals? Is the increase in 
glucagon during a high protein meal necessary to increase insulin? Is GLP-1 vs. 
glucagon necessary for different phases of insulin secretion? Are both GLP-1 and 
glucagon synergistic or additive in insulin control? All of these are possibilities. 
However, in animals devoid of both GLP-1 and glucagon, insulin response to an 
intravenous and oral glucose load appear to be normal suggesting that GLP-1 and 
glucagon, together, are not necessary for insulin secretion and/or that redundant in vivo 
mechanism are able to compensate (142). As has been suggested before, it could be 
that glucagon offers an additional redundant signal that allows for fine-tuning of glucose 
control in the face of metabolic stress whether it is exercise, hypoglycemia, or 
postprandial glucose control.   
Targeting α-cell production of GLP-1, specifically, in T2DM therapeutics is an idea that is 
being explored. One study used adenovirus-mediated expression of PC1/3 in α-cells to 
increase islet production of GLP-1 and was able to improve glucose-stimulated insulin 
secretion in a mouse model of type 1 diabetes mellitus (T1DM) (165). In addition, 
pharmaceutical activation of GPR142, a GPCR that is expressed in pancreatic islets 
and that has previously been shown to enhance glucose-dependent insulin secretion 
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(166,167), also increases GLP-1 secretion from the α-cell (168). Moreover, using 
isolated mouse islets treated with Ex9, the researchers showed that insulin secretion 
induced by GPR142 activation is dependent on GLP-1 (168). Thus, regardless of our 
understanding of the physiology or pathophysiology of islet produced GLP-1, these data 
suggest that this pool of GLP-1 could be targeted to treat T2DM and avoid some of the 
CNS side-affects (ie. nausea) associated with long-acting GLP-1 agonists.  
Bariatric surgery and GLP-1 
Why does GLP-1 increase with surgery?  
Bariatric surgery is currently the most effective strategy at treatment of obesity and its 
co-morbidities. There are many types of bariatric surgeries. Roux-en-Y gastric bypass 
(RYGB; a small gastric pouch is formed and the jejunum is connected directly to the 
small pouch) used to be the most widely performed bariatric surgeries but its utilization 
has been reduced to about 20% of the procedures in the last couple of years (169). 
Currently the most common surgery in the US is vertical sleeve gastrectomy (VSG; 80% 
of the stomach along the greater curvature is removed) which comprises about 60% of 
performed bariatric procedures. The switch is likely due to the fact that VSG is surgically 
more simplistic, leads to fewer long-term malabsorptive issues, and although dogma 
persists that it is less effective, randomized clinical trials demonstrate similar efficacy 
between VSG and RYGB (see (170) for meta-analysis).  
Among the many similar physiological effects between these two surgeries is about a 
10-fold increase in postprandial levels of GLP-1; something observed in both patients 
and rodent models of surgery (171–174). A long-standing hypothesis for why GLP-1 
(and other gut peptides for that matter) are increased after RYGB is that the shorter 
length of small bowel leads to more rapid nutrient delivery further down into the GI tract 
where the majority of L-cells are located (175). VSG also increases nutrient delivery to 
the distal gut thanks to a restricted stomach size that increases gastric pressure (176) 
and consequently gastric emptying rate (176,177). Indeed, speed of nutrient delivery 
may be important after RYGB as the increase in nutrient-induced GLP-1 was eliminated 
if nutrients were delivered to the bypassed limb (178).  However, in rats after VSG, 
glucose infused slowly and directly into the duodenum caused similar increases in GLP-
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1 as when the same glucose load was delivered orally (176). These data suggest that 
intestinal L-cells are either increased in number or in nutrient-sensitivity after VSG. 
While one study demonstrated that VSG in rats increased L-cell number (179) another 
did not (180). Differences in diet as well as the control groups utilized (pair-fed vs. ad lib 
fed sham groups) could lead to differential structural and functional changes in the gut 
nutrient-sensing pathways (181). On the other hand, RYGB is more consistently 
associated with intestinal hypertrophy regardless of dietary exposure (179,182). The 
intestine is considered a major site of glucose disposal after RYGB and this may 
provide energy for intestinal metabolic pathways to support tissue growth (183). In 
humans, this increase in glucose absorption after RYGB was associated with the 
exaggerated release of insulin and GLP-1 (184). Thus, the anatomical differences 
between the surgeries may lead to different adaptations in either the morphological or 
mechanical function of the GI tract and either of these adaptations can regulate prandial 
GLP-1 responses.  
Another common physiological response to both RYGB and VSG is the significant 
increase in total and various subspecies of plasma bile acids (185–187). Bile acids have 
demonstrated effects on stimulating GLP-1 secretion from L-cells by acting through a 
specific G protein-coupled receptor (TGR5) vs. their other common receptor a nuclear 
transcription factor, farnesoid X receptor (FXR) (188).  However, surgery-induced 
increases in bile acids have been demonstrated to be important for the increase in 
postprandial GLP-1 in one (189), but not another study (190). Further, these two studies 
had divergent results on the necessity of TGR5 for surgery-induced weight loss and 
improvements in glucose homeostasis (189,190). Conversely, FXR seems to be 
necessary for the full effects of VSG, independent of GLP-1 (191). Thus, although this 
will require future validation, it seems that the surgery-induced increase in GLP-1 is due 
to intestinal responses to nutrient delivery. With RYGB, this is more acute, but with 
VSG, chronic adaptations are more critical.  
GLP-1 as mechanism for the metabolic success of surgery 
Although T2DM is thought to be chronic and progressive, bariatric surgery leads to large 
improvements in insulin secretion and sensitivity which results in a remission of T2DM 
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for many patients. The consistency of the finding that GLP-1 increases with surgery in 
addition to this increase being associated with greater prandial insulin release (174) and 
greater weight loss (192) after surgery has led to the suggestion that GLP-1 is an 
integral mechanism for the success of surgery. While the postprandial GLP-1 response 
may be required for the insulin and glucose responses to a meal after bariatric surgery, 
whether GLP-1 is responsible for resolution of T2DM is less clear. One study found that 
postprandial GLP-1 responses were a significant predictor of T2DM remission after 
RYGB (193), yet another found similar postprandial GLP-1 responses 2-years after 
VSG whether the patients had postoperative remission, relapse, or lack or remission of 
T2DM (172). 
In support of a role for GLP-1, multiple studies have demonstrated that administration of 
the GLP-1 receptor antagonist, Ex9, reduces the insulin response to a glucose load in 
both humans and rodents (194–197). However, these data come with an interpretative 
problem (198). There is no dispute that GLP-1 regulates postprandial insulin. The same 
dose of Ex9 impairs glucose and reduces insulin in control subjects (172) and rats 
(197). The degree of this impairment is similar between surgery and control conditions. 
If GLP-1 was more important in glucose control after surgery, the degree of impairment 
should be greater. Thus, the question is whether what we are seeing after surgery is 
reflective of the normal response or is reflective of greater importance of GLP-1 during 
surgery.    
The incretin effect is credited to both GLP-1 and GIP (199,200) with each thought to 
contribute equally to insulin secretion in non-obese, non-T2DM subjects (199). Both 
T2DM and to a lesser extent, obesity, reduce (201,202), while bariatric surgery 
enhances, the incretin effect (203). However, there is little agreement as to whether 
bariatric surgery leads to an increase in GIP suggesting that the extent to which GIP 
contributes to the enhanced incretin effect is debatable. In an effort to determine the 
importance of GIP after RYGB, RYGB patients were given a DPP4 inhibitor to increase 
bioavailability of both GIP and GLP-1 and then combined this with Ex9 to block GLP-1R 
signaling; an experimental condition that would isolate the impact of GIP signaling on 
glucose tolerance (204). The DPP4 inhibitor failed to improve glucose tolerance or β-cell 
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function while GLP-1R signaling was blocked in RYGB patients. In contrast, T2DM 
patients that had not undergone bariatric procedures fully responded to the DPP4 
inhibitor with improved glucose tolerance and insulin secretion even when combined 
with Ex9 (205). Together these data suggest that RYGB shifts the balance of the 
incretin effect toward GLP-1 and away from GIP. 
Qualitatively, rodents and humans respond similarly to bariatric surgery. Both have 
substantial weight loss, elevated gastric emptying rate, and increased postprandial 
insulin and GLP-1 levels. While human work is limited to acute pharmacological 
intervention, preclinical work offers the additional ability to genetically manipulate the 
GLP-1 system and test its role in the metabolic success of surgery. One would hope 
that this would lead to less interpretive issues. Whole-body GLP-1R KO mice have 
similar weight loss and improvements in glucose tolerance compared to littermate 
controls after both VSG (206,207) and RYGB (208) suggesting a limited role of GLP-1R 
in surgical success. Central nervous system GLP-1R have been shown to be important 
for regulating body weight and glucose homeostasis in rodents (89,90,95) and may be a 
target population for the impact of surgically-induced GLP-1 to act in regulating body 
mass and glucose. However, Ex9 infused directly into the CNS of rats during RYGB or 
sham surgeries (208) had no significant impact on the surgery-induced reductions in 
body mass. Thus far, the data would seem to be in agreement that GLP-1R signaling is 
not necessary for the metabolic success of surgery. However, in the last few years, 
conflicting reports have been published. To examine the specific role of β-cell GLP-1R, 
two slightly different versions of an inducible Cre-loxP strategy was used to knock out 
these receptors and VSG was performed. One study found that β-cell GLP-1R were 
necessary for surgery-induced improvements in glucose tolerance and glucose-
stimulated insulin secretion, but not weight loss (209); while the other found not only 
that these receptors were not necessary for VSG-induced improvements in glucose 
tolerance but that glucose responses were essentially normalized to the WT levels 
(210). Differences in diet, mouse models, and/or some other factor may contribute 
either independently or in combination to the differences in these experimental findings. 
Regardless, we are still left with no solid conclusion as to whether GLP-1 is necessary 
for the success of surgery.  
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The increase in GLP-1 after surgery may also have a trophic effect on β-cell mass. 
GLP-1 increases β-cell mass in rodents, and has also been suggested to increase β-cell 
function in humans following bariatric surgery (211). In isolated islets, VSG mice had 
changes in their genetic and functional signature favoring calcium signaling and insulin 
secretion (212). In a pooled group of VSG and RYGB patients, pancreatic fat deposition 
as assessed by PET imaging was found to be reduced alongside improvements in β-cell 
function (213). These data suggest the possibility that the impact of surgery on the 
pancreas could be due to the weight loss itself and is independent of GLP-1’s trophic 
effect.  
With both human and rodent work, the clear finding is that the increase in postprandial 
GLP-1 drives acute glucose responses to a meal after bariatric surgery but whether or 
not they are required for long-term improvements in glucose control, T2DM remission, 
and/or for weight loss are debatable. However, this may be difficult to determine as the 
degree of β-cell destruction prior to surgery may be more critical in determining whether 
those β-cells can recover sufficiently to resolve T2DM (214).  
GLP-1 in post-bariatric hypoglycemia 
One increasingly recognized surgery complication is post-bariatric hypoglycemia (PBH) 
(215). This is reflected in a subset of bariatric patients and is associated with symptoms 
of postprandial “dumping syndrome” characterized not only by hypoglycemia, but also 
hyperinsulinemia, sweating, nausea or vomiting, and heart palpitations. Given that 
adrenergic and cholinergic symptoms in the postprandial state can be nonspecific, PBH 
has recently been re-defined as the presence of neuroglycopenic symptoms (difficulty 
thinking, weakness, fatigue) with concomitant hypoglycemia (<54 mg/dL) (215) that is 
relieved within minutes of carbohydrate ingestion. This condition threatens the safety of 
affected patients as hypoglycemia impairs cognition and increases the risk for syncope, 
cardiac arrhythmias, seizures, coma, and even death. Moreover, many patients may be 
rendered unable to perform job-related tasks or to safely operate a motor vehicle.      
Initial reports indicated a prevalence of <1% for hypoglycemia requiring hospitalization, 
but 10% for clinically recognized hypoglycemia (216,217). However, the use of 
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continuous glucose monitoring (CGM) has highlighted that hypoglycemia occurs much 
more frequently (closer to 30%), and is observed with similar frequency in both RYGB 
and VSG (218–220). Using CGM, one study found that 75% of post-RYGB patients had 
glucose levels of <55 mg/dl compared to no hypoglycemia in nonsurgical controls (221). 
Given the increasing numbers of bariatric procedures, and that hypoglycemia typically 
emerges only after 2-3 years postoperatively, the prevalence of PBH is likely to further 
increase over the next decade.   
Hypoglycemia is a complication for T1DM and T2DM, but for those patients medications 
can be adjusted to minimize occurrence. The mechanism for PBH is unknown and 
creates a difficult therapeutic challenge. The dominance of postprandial timing indicates 
that hypoglycemia is partly due to exaggerated systemic appearance of ingested 
glucose secondary to altered anatomy and subsequent disproportionate insulin 
response to a meal. In healthy individuals, regulation of postprandial glucose excursions 
is tightly controlled by regulating the rate of nutrient entry and hormonal responses that 
coordinate nutrient assimilation. Both RYGB and VSG alter many steps in this 
assimilation process including more rapid pouch or gastric emptying, increased glucose 
absorption, increased postprandial GLP-1, and finally markedly increased insulin 
secretion and sensitivity (Figure 1.5). Thus, most initial treatment strategies focus on 
reducing simple carbohydrate intake or using medication to slow carbohydrate 
absorption in order to minimize glucose and consequently insulin “spikes” (222). 
Strategies to reduce insulin itself have also been used including somatostatin analogues 
(e.g. octreotide), diazoxide (reduces insulin secretion), partial pancreatectomy, and 
reversal of the surgical procedure toward normal anatomy if possible. Unfortunately, all 
of these therapies are limited by side effects or incomplete efficacy, even 
pancreatectomy and surgical revision.  
One hypothesis is that this phenomenon is caused by the exaggerated postprandial 
GLP-1 and consequently insulin levels. Postprandial glucose, GLP-1, and insulin have 
been found to be even higher in patients susceptible to PBH (223). Multiple studies 
have now demonstrated that administration of Ex9 can lower postprandial insulin and 
prevent hypoglycemia in RYGB patients (224–227). However, patients with PBH still 
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have higher peak glucose levels after GLP-1R antagonist treatment compared to 
asymptomatic patients. In addition, the rapid time course of the post-surgical increase in 
postprandial GLP-1 and insulin secretion (days) does not mirror the delayed 
development of PBH (years). Importantly, although GLP-1 is likely not a mechanism for 
PBH, Ex9 therapies may still be a way to treat PBH.  
In conclusion, GLP-1 increases with bariatric surgery are likely due to acute and/or 
chronic responses to rapid nutrient entry seen with RYGB and VSG, respectively. This 
increase in GLP-1 likely plays an important role in the acute glucose and insulin 
responses to a given meal. However, whether these increases are responsible for the 
overall improvements in glucose homeostasis, body mass, or in the onset of PBH is 
something that is still debated.  
Targeting GLP-1 in Pharmacology 
GLP-1 agonists and DPP4 inhibitors 
The development of GLP-1-based drugs has been one of the major advances in 
diabetes medicine in recent years. The currently approved pharmaceutical strategies 
targeted to the GLP-1 system are aimed at either increasing endogenous GLP-1 levels 
with inhibitors for the protease that inactivates GLP-1 or long-acting GLP-1R agonists 
resistant to DPP4 cleavage (228,229). DPP4 inhibitors are effective at stimulating 
insulin and reducing glucagon actions; attributes that are credited to GLP-1R signaling 
(230). However, DPP4 acts on GIP as well 40 additional substrates (231). GIP is the 
only additional substrate of note for glucose regulation and work in both humans 
(205,232) and mice (161,233) suggest that both GIP and GLP-1 signaling are targets for 
the improved glucose control with these drugs.  
There are now multiple GLP-1R agonists currently available for the management T2DM 
(229,234,235). Various strategies are used to extend the half-lives of these agonists 
compared to native GLP-1 including using a synthetic analogue of Ex4 (Byetta) and the 
addition of a fatty acid side chain to native GLP-1 to facilitate albumin binding 
(Liraglutide/Victoza). In an effort to improve convenience and compliance (236), 
modifications of these drugs are also being made to extend the half-life to allow for 
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once-weekly injections (Bydureon and semaglutide/Ozembic). Besides being more 
convenient for the patient, there seem to be added benefits of creating a more stable 
pharmacodynamics profile (ie. reducing the peaks and troughs of drug action) as these 
drugs induce less nausea, a common side-effect of rapid acting compounds (237–240). 
An added benefit of these drugs compared to DPP4 inhibitors is the added weight loss 
(241) and for some specific GLP-1R agonists (liraglutide and semaglutide) there is a 
reduction in cardiovascular events (242). Because of the impact of these drugs on 
weight loss, there are now multiple formulations approved to specifically treat obesity 
independent of T2DM. Interestingly, although T2DM patients do see improvements in 
body mass, there is a larger benefit for the obese non-diabetic patient for weight loss.  
The neural pathways leading to the weight loss effects of these drugs are being actively 
pursued in preclinical work. Part of the reason for this effort is to determine whether the 
neural circuitry that drives the weight loss effect is distinct from the circuitry that drives 
the nausea effect of these drugs. In animal work, we know that some neuronal regions 
regulating the impact of GLP-1 on food intake are distinct from those regions that 
regulate nausea (243,244). As discussed above, previous preclinical work in mice and 
rats established that the CNS (97,245), but not the peripheral nervous system (97) is 
critical in mediating the impact of long-acting GLP-1R agonists on body mass. With 
newer advances in neuroscience techniques, we now know that glutamatergic rather 
than GABAergic neurons (98) are the specific type of neurons necessary for the ability 
of liraglutide to induce weight loss. However, given that neither hypothalamic (Nkx2.1 
neurons), PVN (Sim1 neurons), nor POMC neurons were not necessary for the ability of 
long-acting agonists to reduced body mass (95), the hunt is still on for the specific 
population of neurons responsible for the pharmaceutical reduction in body mass. Better 
understanding of the neural mechanisms of these processes would benefit the 
therapeutic utility of these agents.  
Poly-agonists  
An exciting recent pharmaceutical strategy to the treatment of obesity and T2DM has 
been the development of hybrid peptides that activate more than one receptor to 
generate an effect (246). Given that obesity and T2DM are diseases with integrated 
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pathology, a multi-faceted approach is likely necessary for more effective treatment. 
These agents are touted as mimicking the broad range of peptide increases seen after 
bariatric surgery. Some of the first compounds developed using this strategy were 
glucagon/GLP-1 co-agonists, peptides engineered to activate the cognate receptors of 
both peptides in different relative potencies (247,248). The rationale behind this line of 
drug development is that both glucagon and GLP-1 bind specific and distinct receptor 
populations in the brain to cause satiety (249,250), and activating both receptors could 
lead to synergistic effects. Peptides with equal agonism for each of the target drugs (eg. 
GLP-1/glucagon) seem to have the most therapeutic promise (247,248). In the case of 
glucagon, greater glucagon potency would lead to greater energy expenditure and 
suppression of food intake, but there seems to be a threshold beyond which glucose 
control worsens despite weight loss. The results for combined agonism in mice and rats 
are promising with improved glucose tolerance but also greater reductions body weight 
and fat with the dual agonists compared to GLP-1R agonism alone (247,251). Although 
there may be subtleties in formulation that lead to species differences, the results in 
humans have not been as exciting as in mice. Specifically, a recent phase 2a clinical 
trial found reductions in body weight and improvements in glucose control but the 
degree of the improvements seemed to be within the range of what is seen with long-
acting GLP-1R agonists alone (252,253). Interestingly, a GIP receptor/GLP-1R dual 
agonist in phase 2 trials caused greater improvements in both HbA1c% and weight loss 
compared to the GLP-1 agonist alone (254). Given that GIP is thought to be important 
for lipogenesis, the mechanism for this effect of the dual agonist is unclear. Regardless, 
this drug shows great promise in improving glucose control and weight loss in T2DM 
patients. 
Conclusions 
GLP-1 was suggested to be an incretin over 32 years ago. Indeed, GLP-1 actions in the 
islet are implicated in the success of surgery and have been exploited for effective 
glucose control in T2DM patients. However, the incretin model is much too simple for 
the complexity of the system. GLP-1 has a wide array of physiological effects that go 
beyond the β-cell. Further, GLP-1 and glucagon released from the α-cell may be 
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important for β-cell proliferation and function suggesting that paracrine regulation of the 
β-cell needs to be incorporated into our thinking surrounding GLP-1 function. These 
interesting interactions and/or overlapping functions of GLP-1 and glucagon and GPCR 
signaling requires further exploration. What is true, is that GLP-1R agonists are safe 
and effective therapies for obesity and T2DM and will remain an active area of 
exploration. 
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Figure 1.1 The incretin effect: Glucose levels are lower while insulin levels are higher when the same dose of 
glucose is administered directly into the gut versus when administered intravenously (IV). This difference in 
insulin between the gut and venous infusion is the “incretin effect” which occurs in response to GLP-1 and GIP 














Figure 1.2 Intestinal GLP-1 secretion: Several factors have been linked to GLP-1 secretion. The 
parasympathetic nervous system (PNS) stimulates GLP-1 secretion via cholinergic muscarinic receptors (MR). 
Activation of α-adrenergic receptors (AR) stimulates while activation of β-adrenergic receptors inhibits GLP-1 release. 
Various GPCRs including ones activated by bile acids and various fatty acids stimulate GLP-1 through PKA signaling 
and increases in calcium-induced exocytosis. Lastly, direct glucose sensing, predominantly via SGLT1 in humans, 









Figure 1.3 Factors that impact α-cell GLP-1 production. Metabolic stress, systemic inflammation, exercise, 
hyperglycemia, obesity, and diabetes stimulate α-cell GLP-1 production. IL-6 seems to be a primary factory that leads 













Figure 1.4 Recent work highlights a more complexity to the role of Gcg-derived peptides in the incretin effect. 
While historical work suggest intestinal GLP-1 is important in regulating glucose homeostasis, there may be a role for 
α-cell derived GLP-1 as well. In addition, in response to amino acids, glucagon is secreted and acts on local GLP-1R 













Figure 1.5 Postprandial GLP-1 increases several-fold after bariatric surgery and has been implicated as a 
mechanism in both positive and negative impacts of bariatric surgery. On the positive side, GLP-1 has been 
implicated in increasing postprandial insulin levels to restrain postprandial glucose homeostasis improvements in 
insulin sensitivity lead to reductions in fasting insulin, improved hepatic insulin sensitivity, and overall improved β-cell 
function. However, on the negative side, the increase in postprandial insulin is thought to contribute to post-bariatric 

















CHAPTER 2                                                                                                                                    
Premise and Hypotheses for the Role of GLP-1 in Regulation of Inflammation 
Introduction 
One predominant theory explaining the link of obesity to type 2 diabetes mellitus 
(T2DM) involves the obesity-induced chronic low-grade inflammation, or meta-
inflammation. This is because inflammation itself has been linked to impaired glucose 
homeostasis including insulin resistance (255–257). In contrast to the inflammatory 
response to an infection, where the purpose of immune cells is to identify, locate, and 
dispose of foreign microorganisms and viruses, the low-grade inflammation associated 
with obesity is not directed to a specific pathogenic target. Yet, similar to infection-based 
inflammation, meta-inflammation still results in increased accumulation of immune cells 
in metabolic tissues and increased systemic and organ-specific levels of cytokines 
(255,258,259). This includes accumulation of macrophages, phagocytotic cells that are 
either resident within an organ or that migrate from other tissues and play a large role in 
organizing immune responses to promote either a pro- or anti-inflammatory state (260). 
The reverse is also true, that metabolic dysfunction impairs immune responses. For 
example, T2DM patients have impaired immune responses including neutrophil function 
and T cell responses to an infection (261–263). T2DM also worsens the mortality 
prognosis for sepsis, which is hypothesized to be due to innate immune dysregulation, 
such as macrophages and natural killer cells, and adaptive immune suppression, such 
as T cells and B cells (264–266). This complex interaction between T2DM and the 
immune system remains an important inquiry for researchers as there are currently no 
therapeutics that increase survival to sepsis (267). Thus, the search for those critical 
signals that link inflammation and metabolism is critical for treating inflammatory and 
metabolic diseases.  
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Glucagon-like peptide 1 (GLP-1) is a peptide made within intestinal L-cells, pancreatic 
α-cells, and a small cluster of neurons in the hindbrain (10–12). GLP-1 is predominantly 
studied for its role in facilitating postprandial insulin secretion and sensitivity, and 
consequently regulation of glucose homeostasis (26,27,37,38,57,142). In addition to 
glucoregulation, activation of the GLP-1R in the CNS decreases food intake (243,268). 
Although its role in regulating glucose metabolism and food intake has been extensively 
studied, there is also an emerging connection between GLP-1 and the immune system 
(151,269). Data demonstrate that in response to nutrients, circulatory GLP-1 comes 
primarily from the intestine (37,38,42,43). During severe inflammation, the pancreas and 
intestine increase GLP-1 tissue content in response to IL-6 or lipopolysaccharides (LPS) 
(151). However, a key unanswered question is whether there is a physiological 
contribution of the pancreas and/or the intestine to the increase in circulating GLP-1 
and, if so, what is the function of that increase. One possibility is that the physiological 
role for this increase in GLP-1 is similar to postprandial conditions, i.e. to regulate 
glucose and/or energy homeostasis during inflammation. However, pharmacological 
data suggest that at least in bone marrow derived macrophages, GLP-1 signaling 
directly regulates macrophage accumulation and polarization (270). While type 1 
diabetes mellitus (T1DM) has long been studied in association with macrophage 
accumulation in the pancreas, only recently have researchers begun to look at 
macrophage expansion in the islets in T2DM patients and animal models (271–273). 
For example, recent studies have demonstrated that macrophage accumulation within 
the pancreas occurs in response to dietary-induced obesity and that this plays a role in 
impaired glucose-stimulated insulin secretion (259) and with inflammatory stress (272). 
Collectively, these data indicate a need to understand the interaction between meta-
inflammation in the pancreas and the protective role GLP-1 might be playing. To 
investigate the physiological role of Gcg, the gene that encodes GLP-1, GLP-2, 
glucagon and other peptides, under inflammatory conditions, I utilized a well-established 
model to induce severe inflammation, LPS, in combination with the low-grade 
inflammation seen with high-fat diet (HFD). To distinguish the role of pancreatic and 
intestinally produced GLP-1, I used our lab’s Cre lox-P Gcg reactivation model which 
limits expression to either the pancreas or the intestine (274). I hypothesized that 
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increased GLP-1 plays a metabolic role, functioning to regulate glucose levels and food 
intake, and an immunologic role, functioning to decrease inflammation. 
Thus, the goal of this proposal is to determine the physiological role of GLP-1 in the 
regulation of immune cell accumulation and polarization, and downstream metabolic 
processes during infection-based inflammation and the impact of HFD.  
Specific Aims 
Aim 1. To test the hypothesis that high-fat diet and impaired glucose tolerance increase 
inflammatory responses to LPS-induced inflammation. 
High-fat diet (HFD) is known to result in an increase in inflammatory cytokines and 
impaired glucose control. Studies in humans have shown that obesity and impaired 
glucose control impairs immune responses to severe inflammatory conditions. Using 
wild-type mice on HFD, I explored how impaired glucose tolerance and chronic low-
grade inflammation affect GLP-1 levels, glucose, insulin, cytokine expression, and 
feeding responses to an inflammatory insult induced by exogenous administration of 
LPS. I hypothesized that HFD will exacerbate the physiological responses to LPS, 
including increased GLP-1, sickness-induced anorexia and inflammatory responses 
compared to chow-fed mice.  
Aim 2. To test the hypothesis that pancreatic- and intestinally produced GLP-1 regulates 
metabolic responses to severe inflammation   
Our lab used Cre-loxP technology to limit Gcg, the gene that encodes GLP-1, 
expression to either the pancreatic α-cells or intestinal L-cells. These animals were 
placed on normal chow or HFD and feeding responses to LPS administration were 
assessed to determine whether Gcg is necessary for the anorectic effect of LPS. 
Additionally, I determined whether intestinal, pancreatic, or both sources of GLP-1 are 
necessary for the acute glucose response, systemic and pancreatic inflammatory 
responses to LPS administration. I hypothesized that pancreatic GLP-1 plays a 
paracrine role in glucose regulation under LPS-induced inflammation and that both 




Aim 3. To test the hypothesis that pancreatic GLP-1 regulates local macrophage 
accumulation in the pancreas during severe inflammation 
Our preliminary data suggests that the pancreas contributes to circulatory GLP-1 after 
LPS administration. Again, I used our chow vs. HFD Cre-loxP Gcg model, animals 
received LPS or vehicle treatment and through a combination of flow cytometry and 
immunohistochemistry (IHC) techniques, I characterized the immune cells that 
accumulated within the pancreas after LPS. Then I used a Glp1r-GFP reporter mouse to 
determine whether immune cells in the pancreas expressed Glp1r.  I hypothesized that 
pancreatic GLP-1 promotes a local anti-inflammatory state and works to restrain the 
LPS-induced immune response, thus fewer macrophages will accumulate within the 
islet when GLP-1 is present.
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CHAPTER 3                                                                                                                               
The Role of GLP-1 in the Regulation of Metabolism and Immune Responses  
Abstract 
While GLP-1 is classically described as an incretin hormone, it is known to be increased 
by the pro-inflammatory cytokine, interleukin 6 (IL-6), in both the pancreatic α-cells and 
intestinal L-cells. Interestingly, the activation of the endogenous GLP-1 system is 
exaggerated in type 2 diabetes mellitus (T2DM) patients under an inflammatory 
stimulus. However, the function of GLP-1 during an inflammatory state is unknown. 
Using a combination of high-fat diet (HFD)-induced obesity and our innovative mouse 
model of tissue-specific Gcg (the gene that encodes GLP-1) expression, I explored the 
function of GLP-1 in response to inflammation by administering lipopolysaccharide 
(LPS), a well-established tool for inducing inflammation. LPS is also suppresses feeding 
and impacts glucose homeostasis; both functions of GLP-1. I hypothesized that HFD 
would exacerbate physiological responses to LPS including increased plasma GLP-1, 
decreased blood glucose levels, and increased sickness-induced anorexia, as well as 
systemic inflammatory responses including increased plasma cytokines. I found that 
HFD increased LPS-induced suppression of feeding and increased plasma levels of 
both pro-inflammatory cytokines and GLP-1. I hypothesized that increases in GLP-1 in 
response to LPS were necessary for the feeding and glucose responses to LPS. To test 
this hypothesis, I examined the role of tissue-specific GLP-1 in the metabolic and 
immunologic responses to LPS. I found that while both pancreatic and intestinal Gcg 
expression contribute to LPS-induced increases in GLP-1, Gcg was not necessary for 
the glucoregulatory or feeding responses to LPS. However, whole-body Gcg Null 
animals had increased the macrophage accumulation in the pancreas. Lastly, using a 
GLP-1R reporter mouse, I found that macrophages that accumulate in the pancreas 
after LPS express the GLP-1R. Altogether these data suggest that pancreatic 
production of GLP-1 directly regulates macrophage responses to inflammation. I 
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conclude that under severe inflammatory conditions, GLP-1 plays an immunologic, 
rather than metabolic role, through direct macrophage regulation.  
Introduction 
Within a few decades, obesity has risen in prevalence at an alarming rate and now 
affects more than a third of US adults (275). Obesity and its concomitant comorbidities 
are an urgent public health concern and burden on the healthcare system. Patients with 
obesity are more likely to develop hypertension, cardiovascular disease, osteoarthritis, 
and Type 2 Diabetes Mellitus (T2DM). T2DM is characterized by insulin resistance, 
dysregulated glucose control, and impaired islet function. Prevalence of T2DM is rising 
in parallel to obesity worldwide (276,277). In addition to developing co-morbidities, 
T2DM patients are at an increased risk for complications associated with inflammation. 
For example, T2DM patients are at an increased risk for both developing infections that 
lead to sepsis and mortality associated with sepsis (255,257,262). In 2020, the COVID-
19 pandemic highlighted the need to understand the link between T2DM and severe 
inflammatory responses (278).  
One predominant theory explaining the link of obesity to type 2 diabetes mellitus 
(T2DM) involves the obesity-induced chronic low-grade inflammation. In contrast to the 
inflammatory response to an infection, where the purpose of immune cells is to identify, 
locate, and dispose of foreign microorganisms and viruses, the low-grade inflammatory 
state associated with obesity is not directed to a specific pathogenic target. Yet, similar 
to infection-based inflammation, meta-inflammation results in increased accumulation of 
immune cells in metabolic tissues and increased systemic and organ-specific levels of 
cytokines (255,258,259). The reverse is also true, that metabolic dysfunction impairs 
immune responses. Macrophages are essential for detecting, engulfing, and destroying 
apoptotic cells and inflammatory stimuli, typically a pathogen such as a virus or 
bacteria. During severe inflammation, tissue damage and hyperinflammation can result 
in an accumulation of neutrophils and other immune cells to remove damaged cells and 
regulate the immune response within an organ (279,280). While macrophage function 
and accumulation in the pancreas has been well studied in type 1 diabetes mellitus 
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(T1DM), recently, researchers have seen that macrophages also accumulate in the 
islets of T2DM patients and obese animal models (271–273). Under steady state 
conditions, macrophages within the islets are myeloid derived and express IL1-β and 
TNF-α (281). These tissue-resident macrophages are established prenatally and self-
maintained, and distinct from circulating monocytes (282). Severe inflammation 
(modeled by exogenous administration of lipopolysaccharide; LPS) will increase 
inflammatory transcripts from islet-resident macrophages (283). Recent research has 
shown that macrophages accumulate within the islet during diet-induced obesity leading 
to elevated levels of pro-inflammatory cytokines (259). Similarly, recent work 
demonstrates that during obesity, islet-resident macrophages proliferate contributing to 
a local inflammatory state and this results in impaired β-cell function (259,283). 
Collectively, these data indicate growing evidence that pancreatic 
inflammation/macrophage accumulation occurs with obesity and this contributes to 
impaired β-cell function. The impact of COVID-19 on islet function supports the 
importance of studying pancreatic inflammatory responses (284).  
One islet-derived factor that increases with both inflammation and metabolic stress is 
glucagon-like peptide-1 (GLP-1). GLP-1 is classically described as an incretin hormone, 
coded by the preproglucagon gene (Gcg). Gcg is expressed in the α-cells of the 
pancreas, the L-cells of the intestinal tract, and in the nucleus of the solitary tract (NTS). 
As a metabolic hormone, GLP-1 is increased after a meal, secreted predominantly from 
the intestinal L-cells and functions to decrease blood glucose in an insulin-dependent 
manner (37,38,42,43). GLP-1 has one known receptor (GLP-1R), a G-protein coupled 
receptor (GPCR), that is primarily found on the cellular membrane of pancreatic β-cells, 
and in nerve terminals in the wall of the hepatic portal vein, the lung, and within the 
brain (25). Activation of these GLP-1R in the CNS decreases food intake (243,268). The 
primary product of Gcg within the pancreas is glucagon. However, with metabolic and 
inflammatory stress, there is increased pancreatic production of GLP-1 
(139,143,285,286). While the physiological function of this increase in pancreatic GLP-1 
during an immune response remains unknown, pharmacological GLP-1 agonists have 
been found to have an anti-inflammatory effect (287,288) and in vitro work has shown 
that GLP-1 agonist treatment decreases TNF-α mRNA expression from macrophages 
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under LPS-induced inflammation (270). Previously, our lab discriminated between the 
roles of pancreatic and intestinal GLP-1 and have found that pancreatic GLP-1 is critical 
in regulating glucose homeostasis using our validated innovative mouse models 
(142,162,289,290).  Using a combination of high-fat diet (HFD)-induced obesity and our 
tissue-specific Gcg expression mouse model, I explored the function of Gcg-derived 
peptides in response to inflammation. A stated above, LPS is a well-established tool for 
inducing inflammation and is a known anorectic agent that alters glucose homeostasis; 
both functions of GLP-1. I hypothesized that GLP-1 contributes to the anorectic and 
glucoregulatory responses to inflammation. I also predict that pancreatic-produced GLP-
1 functions to regulate the local pancreatic endocrine cell inflammatory state by 
organizing macrophage accumulation as part of a complex cross-talk system between 
immune and endocrine cells. I hypothesized that HFD would exacerbate all these 
responses. 
Methods 
Animal Care  
8-week old C57BL6/J male mice (The Jackson Laboratory) or genetically crossed mice 
(discussed below) were used for all studies and housed in the University of Michigan 
North Campus Research Complex animal facilities under controlled conditions (12:12 
light-dark cycle, 50–60% humidity, and 25°C) with ad libitum access to water, and 
normal chow diet (Chow; Lab Diet, 5L0D) or high-fat diet (HFD; Research Diets 
D12492; 20% Kcal protein, 60% kcal fat, 20% kcal carbohydrate; 5.21 kcal/g) as 
indicated by each study. Intestinal or pancreatic reactivation of the 
endogenous Gcg gene was accomplished as described previously (274). Briefly, Gcg 
Null mice were crossed with villin 1-Cre (Jax Laboratories, stock number 004586) and 
PDX1-Cre (Jax Laboratories, stock number 014647) mice, respectively resulting in 
offspring with Cre-specific reactivation of the Gcg gene, Gcg Null, and Cre littermate 
controls (Con) (274). Glp1r-GFP reporter mice were generated as done previously 
(98,291). Briefly, Glp1rCre/+ mice (Jax Laboratory; 029283) were crossed to EGFP-L10a  
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mice (292) to generate offspring with a GFP labelled Glp1r. The University of Michigan 
Institutional Animal Care and Use Committee approved all procedures. 
Lipopolysaccharide (LPS) Dosing  
At 8 weeks of age, male mice either remained on chow or were switched to HFD for 9-
16 weeks depending on the endpoint of interest to assess the interaction between diet-
induced obesity and metabolic response to severe inflammation. To determine whether 
HFD alters the GLP-1 response to LPS compared to chow, I analyzed plasma levels of 
GLP-1 and glucose before and after LPS administration. To do this, mice were fasted 4 
hours after the onset of light phase. Mice were then administered LPS at a dose 
(100ng/g BW) previously demonstrated to increase plasma levels of GLP-1 (151,269) 
(n=4/diet) or vehicle (n=4/diet) via IP injection. Blood glucose was measured at baseline 
and plasma GLP-1 and blood glucose were measured 2 and 4 hours after LPS via tail 
blood collected in EDTA-coated tubes. Due to the increase in body weight, the HFD-fed 
mice received a higher absolute dose of LPS, the above experiment was repeated 
under the same dietary and experimental conditions except with a flat dose of LPS 
(0.32µg delivered in 0.22mL) (Chow-LPS, n=8; HFD-LPS, n=9) or vehicle treatment 
(Chow-Veh, n=6; HFD-Veh, n=9). The flat dose was calculated based on the average 
dose a chow-fed mouse would receive at 100ng/g LPS dose.  
Food Intake 
On the experiment day, chow or HFD-fed mice were fasted for then 4 hours prior to 
lights out. Immediately before lights out, LPS (100ng/g) or vehicle (0.9% NaCl) was 
administered via IP injection. In one cohort of HFD-fed Gcg Null vs. Cre animals the 
dose was lowered to 50ng/g. Food intake was measured 2, 4, 15, and 24 hours after 
injections.  
Energy Homeostasis  
In order to understand the impact of HFD on changes in energy expenditure during 
severe inflammatory conditions, I utilized indirect calorimetry cages. A cohort of animals 
was generated under the same chow vs. HFD dietary conditions as described above. 
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Mice were housed in PhenoMaster chambers (TSE Systems, Bad Homburg, Germany) 
for 5 days to assess food intake, energy expenditure, and respiratory exchange ratio. 
Mice acclimated to the chambers and 22°C for 2 days prior to the experiment day. Prior 
to lights out, mice received a flat LPS dose (4µg delivered in 0.13mL) (n=6/diet) or 
vehicle (n=6/diet) via IP injection. Mice remained in the metabolic chambers for 3 days 
to monitor recovery from LPS.  
Time Course of Glucose, Glucoregulatory Hormones, and Cytokine Responses to LPS  
Because previous experiments were limited by time points and blood volume that could 
be taken via tail nick, I designed a study to examine the time course responses of 
plasma levels of metabolic hormones and cytokines in response to LPS. A cohort of 
male C57Bl/6J animals was generated under the same chow vs. HFD dietary conditions 
described above. 3-5 days before the experiment, under general anesthesia 
(isoflurane), mice had catheters placed in the carotid artery (MJC-02, SAI Infusion 
Technologies) and jugular vein (BTPU-014, Instech Laboratories Inc.; MRE037, 
Braintree Scientific Inc.). After recovery from surgery, mice regained at least 90% of 
their pre-surgery body weight by study day. On the experiment day mice were fasted 4 
hours after the onset of light phase. To minimize handling of the mice, LPS (4µg 
delivered in 0.13mL) or vehicle was administered via the jugular vein. Blood samples, 
about 200 μL, were collected from the carotid artery in EDTA-coated tubes containing 
aprotinin and dipeptidyl peptidase-4 (DPP-4) inhibitor at baseline, 30, 60, 120 and 180 
minutes post-LPS infusion for assessment of plasma GLP-1, insulin, glucagon, IL-6, 
TNF-alpha, and IL-1β. Additional measures of blood glucose were taken every 30 
minutes throughout the experiment. To maintain blood volume due to the frequent 
sampling, heparin washed red blood cells from donor mice were administered via the 
jugular vein throughout the three-hour experiment at a rate of 4.4µL/minute for a total of 
800µL. During the experiment, I observed stroke-like symptoms in 5 mice and excluded 
these mice from analysis. Following the experiment, animals (Chow-Veh, n=6; Chow-
LPS, n=9; HFD-Veh, n=8; HFD-LPS, n=8) were sacrificed with pentobarbital sodium 




Glucose Tolerance Tests  
To determine if LPS administration has a long-term impact on glucose tolerance and 
whether diet impacted these results, we conducted glucose tolerance tests on male 
mice (n=12/diet) that were generated under the same chow vs. HFD dietary conditions 
described above. Glucose tolerance was assessed 2-3 weeks after an IP injection of a 
flat dose of LPS or vehicle treatment as above. For the IP and oral glucose tolerance 
tests, mice were fasted for 4h after the onset of the light phase. Blood was sampled and 
measured via tail nick. Basal blood glucose was sampled at -15 min, and glucose was 
administered via IP (2g/kg of 25% dextrose) injection or oral (300uL of 25% dextrose) 
gavage. Blood samples were taken at 15, 30, 45, 60, and 120 minutes after glucose 
administration. 
Real-time Quantitative PCR (qPCR)  
To examine systemic cytokine expression, necropsied livers were rapidly removed and 
frozen for later analysis. After homogenization in Trizol reagent, tissue RNA was 
extracted using a Pure Link RNA mini kit (Invitrogen, Carlsbad, CA). cDNA was 
synthesized (iScript cDNA synthesis kit, BioRad, Hercules, CA), and qPCR was 
performed using a TaqMan 7900 Sequence Detection System with TaqMan Universal 
PCR Master Mix (Applied Biosystems, Foster City, CA.). Relative mRNA expression of 
hepatic Il6 (Mm00446190_m1), Tnfa (Mm00443258_m1), IL-10 (Mm01288386_m1) and 
Ccl2 (Mm00441242_m1) were calculated relative to β-actin (Mm02619580_g1) samples 
using the ΔΔCT method. 
Hormone Assays  
Plasma levels of total GLP-1 and IL-6, TNF-alpha, and IL-1β (Mesoscale Discovery, 
Rockville, MD, USA), insulin (Crystal Chem Inc., Elk Grove Village, IL, USA) and 
glucagon (Mercodia, Uppsala, Sweden) were measured using ELISA kits.  
Tissue Macrophage Accumulation  
On experiment day, mice (n=3-4/group) were administered LPS (100ng/g) or vehicle 
treatment via IP injection. 24 hours after administration, mice were euthanized by CO2 
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asphyxiation and pancreas was immediately removed and placed in 10% formalin 
overnight. Tissues were processed for subsequent paraffin embedding and cut into 4 
μm sections for immunohistochemistry staining. The sections were incubated overnight 
with a F4/80 antibody (1:250; Cell Signaling Technology) as a marker of general 
macrophage accumulation and counterstained hematoxylin. The slides were scanned 
using Leica Aperio AT2® scanner and quantified using ImageJ as percent F4/80 area of 
total, islet, or acinar area. 
Macrophage Characterization via Flow Cytometry 
Mouse pancreata (Con-Veh n=5, Con-LPS n=5, Gcg Null-Veh n=5, Gcg Null-LPS n=5; 
HFD-Con-LPS n=5, HFD-Con-Veh n=5, HFD Gcg Null n=4, Gcg Null-LPS n=4; wild-
type n=1, Glp1r-GFP-LPS n=2) were excised immediately after euthanasia and then 
mechanically dissociated with scissors in sterile PBS. Pancreata were washed and 
pelleted under centrifugation, resuspended in 1mg/mL Collagenase V (Sigma), digested 
for 15 minutes at 37°C, quenched with RPMI + 10% FBS, then filtered through 40μm 
filters (Corning). The cells underwent RBC lysis, washed in PBS, then blocked and 
stained with the CD45-PerCP (Biolegend) for total immune cells, CD64-PE (BD 
Biosciences) for macrophages, and CD11b-APC (Biolegend) for a specific 
subpopulation of macrophages at 1:100 dilution in 100% FBS. Separately, bone marrow 
was extracted (Wild-type=1, Glp1r-GFP-LPS n=2), homogenized to a single cell 
suspension and stained with the following antibodies CD45-eFluor450 
(Invitrogen/eBioscience) and CD11b-APC (Invitrogen/eBioscience). The cells were then 
washed in FACS buffer (1% FBS, HBSS), and run on a ZE4 Analyzer flow cytometer 
(BioRad). While I had a validated F4/80 IHC antibody, I tested both F4/80 and CD64 to 
identify macrophage populations with flow cytometry and the CD64 population was 
more distinct for flow cytometry of the pancreas. 
Statistics  
The number of animals studied per treatment and genotype are indicated within each 
experiment and were determined by a power analysis completed using variance from 
previous data. All data are expressed as mean ± SEM. The statistical procedures were 
performed as indicated in the figure legends. Normally distributed data were analyzed 
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via standard parametric statistics including two-way, or three-way ANOVA’s and t-tests. 
If significant interactions were detected between independent variables, Tukey’s post-
hoc analysis was performed to determine where significant differences lie. Statistical 
analyses were performed using GraphPad Prism v.8.1.1, and statistical significance 
was accepted when p<0.05. 
Results 
Impact of LPS on plasma GLP-1 in HFD versus chow-fed mice. 
LPS is a well-established tool to induce inflammation and important for this study, 
increases GLP-1 (151,293,294). Additionally, plasma GLP-1 responses to severe 
inflammation are higher in patients with T2DM (152,295). To determine whether HFD 
alters physiological responses to LPS compared to chow-fed mice, I analyzed plasma 
levels of GLP-1 and glucose before and after LPS administration in chow and HFD-fed 
mice. As expected, HFD for 8 weeks significantly increased body weight (mean ± SEM; 
Chow-Veh 30.2 grams (g)±1.11, Chow-LPS 29.5g±0.95, HFD-Veh 48.4g±2.16, HFD-
LPS 47.9g±2.30, p<0.05) compared to chow-fed mice. As expected, HFD animals had 
greater baseline glucose levels. 2h after LPS, both chow and HFD-fed mice had 
decreased blood glucose levels compared to baseline but HFD animals were still 
significantly higher compared to chow-fed mice (Figure 3.1A). 4h after LPS, there were 
no longer statistical differences between the LPS-treated chow and HFD animals 
indicating a greater relative fall from baseline in HFD-fed mice. Total GLP-1 (Figure 
3.1B) levels were increased with LPS and were significantly greater in HFD-fed 
compared to chow-fed mice 2h after LPS. Consistent with previous work, the LPS dose 
was calculated based on body weight. However, because HFD-fed mice weigh more, 
their absolute LPS dose was higher, which, in and of itself, could increase plasma GLP-
1 levels in the obese animals. To determine if this was the case, I then administered a 
flat dose (0.32ug) to a second cohort of chow vs. HFD-fed mice. Again, HFD 
significantly increased body weight (mean ± SEM; Chow-Veh 32.43g±0.66, Chow-LPS 
32.07g±0.32, HFD-Veh 45.66g±1.86, HFD-LPS 45.43g±1.90; p<0.05). Similar to the 
body weight relative LPS dose, glucose (Figure 3.1C) levels in chow and HFD-fed 
decreased over 4h after LPS and this greater relative decrease was greater in HFD-fed 
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mice. Total plasma GLP-1 (Figure 3.1D) was significantly increased in the HFD- 
compared to chow-fed mice 2 hours after LPS. Taken together, these data indicate that 
HFD alters glucose and the GLP-1 responses to LPS.   
HFD-fed mice have a prolonged anorectic effect in response to LPS compared to chow-
fed mice 
LPS is known to decrease food intake and because of this reduction, conserve energy 
expenditure and alter fuel utilization (296,297). Typically, this results in a shift away from 
carbohydrate oxidation (296). To further examine the interaction between energy 
homeostasis, immune responses, and diet, I utilized metabolic chambers to monitor 
end-points associated with energy homeostasis after LPS. Baseline body weight was 
greater in HFD vs. chow-fed mice but within diet the LPS and Veh groups were matched 
for body weight (Figure 3.2A). Consistent with the literature, LPS-treated mice had a 
significant decrease in body weight (Figure 3.2B) over 4 days. In addition, there was a 
significant decrease in lean but not fat mass 4 days after LPS indicating that the 
majority of the body weight lost was from muscle mass (Figure 3.2C-D). As expected, 
LPS-treated mice decreased their food intake both within hours of administration 
(Figure 3.2E) and this suppression of feeding lasted for 3 days (Figure 3.2F). During 
Day 1 after LPS, the HFD mice had significantly decreased food intake compared to the 
Chow-fed LPS group (Figure 3.2E). As the mice recovered on Day 2 and 3, the HFD-
LPS mice continued to have decreased cumulative food intake compared to chow-fed 
mice (Figure 3. 2F).  
As stated above, a typical response to LPS is a decrease in energy expenditure to 
prioritize immune cell function (296). I found a significantly lower energy expenditure in 
the Chow-LPS vs. Veh group during Day 1 dark cycle and then no significant difference 
between these groups during the first light cycle or after (Figure 3.2G-H) indicating that 
the animals were quickly recovering from the LPS injection. However, the HFD-LPS 
group has similar energy expenditure to their Veh-treated control after LPS (Figure 
3.2G-H) implying that HFD induces a dysregulation of energy prioritization. Because the 
HFD-fed mice have greater body weight, I chose to calculate absolute energy 
expenditure. However, I saw similar results when energy expenditure was expressed 
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relative to body weight as well (Supplementary Figure 3.1). Together these data 
suggest that HFD-fed mice have an increased sickness-induced anorexia and 
dysregulated energy expenditure during severe inflammation.  
Under immune activation, competing metabolic demands of immune cells vs. 
physiological functions must be balanced (296). The respiratory exchange ratio (RER) is 
an indicator of whole-body fuel utilization and was reported for all groups 24h following 
LPS (Figure 3.2I). The average RER (Figure 3.2J) for Day 1 was significantly higher in 
the Chow-Veh group compared to all others, and on Days 2 and 3 both Veh- and LPS-
treated chow groups were significantly higher compared to the HFD-fed groups. These 
RER data show that the chow-fed mice shift away from oxidizing carbohydrates (100% 
carbohydrate oxidation indicated by a RER=1) as an energy source (Figure 3.2I). The 
HFD-LPS mice are already oxidizing fatty acids (100% fatty acid oxidation indicated by 
a RER=0.7) as an energy source at baseline so no decrease in RER is detected. By 
Day 2 after LPS, RER in the chow-fed mice is similar to baseline indicating that they 
have recovered from the LPS administration. Conversely, the HFD-LPS mice dips below 
0.7 on the RER graph, implying the mice are resorting to either fatty acids or ketone 
utilization. Day 3 after LPS, both LPS-treated mice have similar RER to their respective 
control groups.  
HFD-fed mice show increased inflammatory responses to LPS compared to chow-fed 
mice 
Having observed differences in responses to LPS between chow vs. HFD-fed mice, I 
wanted to further explore the systemic physiological and inflammatory responses. Mice 
underwent vascular catherization and LPS (4ug; flat dose) was administered via the 
jugular vein while blood draws were taken from the carotid artery. This is beneficial 
compared to tail bleeding as it allows me to take a higher volume and frequency of 
blood draws because I can maintain blood volume with a constant red blood cell 
infusion, and it is less stressful to the mice compared to repeated tail bleeding. The 
LPS-treated mice had decreased blood glucose levels (Figure 3.3A) and had increased 
plasma GLP-1 (Figure 3.3B) over time relative compared to Veh-treated mice and 
these effects were magnified (Diet x Treatment p=0.02) in mice fed HFD. Interestingly, 
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although insulin was higher in HFD- vs. chow-fed mice, the increase in GLP-1 did not 
result in increased plasma insulin with LPS (Figure 3.3C). The LPS treated mice had 
significantly increased glucagon (Figure 3.3D) levels compared to Veh-treated mice at 
120 and 180min after LPS in both HFD- and chow-fed mice. The pro-inflammatory 
cytokines, IL-6 (Figure 3.3E) and TNF-α (Figure 3.3F), were greater in the HFD-LPS 
group compared to the Chow-LPS group while IL-1β (Figure 3.3G) increased with LPS 
similarly between the two dietary groups. Because the liver is an important link between 
the gut and systemic circulation (298), I evaluated liver cytokine expression in the HFD 
and chow-fed mice. In LPS-treated mice, there is a significant increase of liver cytokine 
expression including IL-6 (Figure 3.3H), TNF-α (Figure 3.3I), IL-10 (Figure 3.3J), and 
MCP-1 (Figure 3.3K) compared to Veh-treatment, but there were no significant 
interactions between diet and LPS. Together these data suggest that HFD-fed mice 
have increased systemic and liver inflammatory responses to LPS compared to chow-
fed mice. 
The role of Gcg in the physiological responses to LPS in chow and HFD-fed mice  
Next, I wanted to determine the function of the increase in GLP-1 in response to LPS. 
The traditional function of GLP-1 focuses on its ability to decrease appetite and increase 
insulin secretion in response to nutrients (37,38,42,43,243,268). However, GLP-1 has 
also been implicated as an anti-inflammatory agent (285,286). To determine the 
necessity of GLP-1 in the metabolic and immunologic responses to LPS, I studied both 
PDX1-Cre and Vil-Cre litter-mate controls (indicated by Con in figures), Gcg Null, 
pancreatic and intestinally Gcg reactivated mice that were fed chow (Figure 3.4A-M) or 
HFD (Figure 3.5A-L). There was no significant impact of genotype on the feeding 
response to LPS (Figure 3.4B-C) demonstrating that Gcg is not necessary, nor is 
pancreatic or intestinal Gcg sufficient, for the anorectic effect of LPS. There was no 
significant change in glucose in response to saline (Figure 3.4D) over time or between 
genotypes. While glucose was significantly lower at 240 min in response to LPS, 
(Figure 3.4E) there was no significant difference in this decrease between the 
genotypes. At 240 minutes after LPS, (Figure 3.4F) total GLP-1 was increased in the 
chow-fed control and GcgRAΔPanc mice and, as expected, was undetected in the Gcg 
49 
 
Null mice. The GcgRAΔInt mice had no significant increase in total GLP-1 levels in 
response to LPS. This indicates that the pancreas is a more significant contributor to 
plasma GLP-1 responses during LPS-induced inflammation. There was no significant 
impact of genotype or LPS on insulin levels (Figure 3.4G). Together these data suggest 
that GLP-1 does not function to increase insulin during severe inflammation and is not 
necessary for the glucose response to insulin. Glucagon (Figure 3.4H) was significantly 
higher in response to LPS in control and GcgRAΔPanc mice and undetectable in both the 
Gcg Null and GcgRAΔInt mice. Several cytokines were significantly increased in 
response to LPS in both the plasma (Figure 3.4I-K) and liver (Figure 3.4L-M) but there 
was no additional impact of genotype. Because genotype did not impact hepatic 
expression of cytokines in the control, Gcg Null or GcgRAΔPanc mice, this endpoint was 
not assessed GcgRAΔInt groups. 
I previously observed difference in total GLP-1 expression in chow versus HFD-fed mice 
under inflammatory conditions, therefore, I also assessed similar endpoints in a 
separate cohort of HFD-fed mice. There was no significant impact of genotype on food 
intake (Figure 3.5A-B) demonstrating that the lack of impact of Gcg on the anorectic 
effect of LPS is not impacted by diet. Similar to chow-fed, there was no significant 
change in glucose in response to saline (Figure 3.5C) over time or between genotypes. 
Glucose was significantly lower at 240 min in response to LPS (Figure 3.5D) but there 
was no significant difference in this decrease between the genotypes. Together these 
data suggest that Gcg does not play a role in regulating glucose, feeding, or systemic 
cytokine responses to LPS, regardless of diet.  
Total GLP-1 was increased in the Con-LPS HFD-fed mice only (Figure 3.5E). When I 
examined the GLP-1 levels after LPS as percent of average saline, the chow and HFD 
control mice contributed about the same levels of total GLP-1 (mean ± SEM; Chow-Con 
289.36±30.02, HFD-Con 238.22±28.31; p=0.25), regardless of diet. The pancreatic 
contribution trended towards being higher in the chow-fed (mean±SEM; Chow-
GcgRAΔPanc 364.40±95.40, HFD-GcgRAΔPanc 196.71±45.07, p=0.08). The intestinal 
contribution (mean±SEM; Chow-GcgRAΔInt 69.21±21.35, HFD-GcgRAΔInt 181.54±40.08, 
p=0.01) increased in the HFD compared to chow-fed mice. These data imply that in 
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chow-fed mice the pancreas was the major contributor but in the HFD-fed mice both the 
pancreas and intestine contribute to circulating GLP-1 levels. In the HFD-fed mice, only 
the Con-LPS group had a significant increase in glucagon (Figure 3.5G). 
Gcg Null mice have increased macrophage accumulation in the pancreas after LPS  
To test whether Gcg had a role in regulating local inflammation, I determined pancreatic 
macrophage accumulation and characterization via two methods: flow cytometry and 
immunohistochemistry. Pancreatic immune cells were sorted on a flow cytometer, and 
the cells were (Figure 3.6A, Figure 3.7A) gated on singlets, scatter, and CD45+ cells. 
The population of interest, CD64+CD11b+, which represents a specific subpopulation of 
macrophages, was quantified and analyzed (Figure 3.6A, Figure 3.7). The Gcg Null-
LPS treated mice had significantly increased macrophage accumulation compared to all 
other groups in the chow-fed mice (Figure 3.6A). In the HFD-fed mice, LPS significantly 
increased CD64+CD11b+ (main effect of treatment (p=0.03)) and the Gcg Null mice had 
significantly greater CD64+CD11b+ cells (main effect of genotype (p=0.04)) but there 
was no significant interaction between the two variables.  
In a separate cohort, LPS was administered and pancreata were collected and 
processed for immunohistochemistry. Slides were stained for F4/80 (Figure 3.6B, 
Figure 3.7B) as general marker for macrophages using DAB. These data were 
quantified as percentage of area positive for F4/80 staining compared to the total 
(Figure 3.6C, Figure 3.7C) islet (Figure 3.6D, Figure 3.7D), and acinar area (Figure 
3.6E, Figure 3.7E), respectively. In both chow and HFD-fed mice, there was an 
increase in F4/80 staining in response to LPS, but this increase was similar in control, 
Gcg Null, and GcgRAΔPanc mice. The Gcg Null HFD mice had a baseline increase as 
shown by the Gcg Null-Veh group. In the acinar (p=0.02) and total (p=0.04) area of the 
HFD pancreata, I found a main effect of LPS treatment. Together, these data imply that 
under severe inflammation, Gcg Null mice have more macrophage accumulation in the 
pancreas compared to control as shown by the CD64+CD11b+ population in the flow 
cytometry, and the IHC demonstrates that the macrophages accumulate in both the islet 




Macrophages isolated from the pancreas express GLP-1R 
Next, I investigated if GLP-1 could be directly regulating macrophage accumulation. 
Whether GLP-1R are expressed on macrophages, and other immune cells for that 
matter, is unknown as GLP-1R antibodies are questionable (299).  To address this 
problem, I crossed an eGFP-L10a reporter mouse to a Glp1rΔCre (Figure 3.8A) mouse. I 
administered LPS and pancreatic tissues were stained for immune cells, acquired on 
the flow cytometer, and gated on singlets, scatter, CD45+, and CD64+ cells (Figure 
3.8B). Validating that I was able to detect the GFP signal, the wild-type mice showed no 
GFP signal (Figure 3.8C), whereas Glp1r-GFP mice showed a strong GFP signal 
(Figure 3.8C). Additionally, this population of GFP+ cells were positive for CD11b+, the 
subpopulation of macrophages I saw elevated in Gcg Null mice. Interestingly, only the 
pancreas showed this population and not immune cells isolated from the bone marrow 
(Figure 3.8C). This implies that under the stress of inflammation, macrophages in the 
pancreas express GLP-1R and are likely directly regulated by locally produced GLP-1.  
HFD-fed mice have impaired IP glucose tolerance 3 weeks after LPS  
To determine whether pancreatic macrophage accumulation after LPS could have a 
long-term effect on endocrine function, chow- and HFD-fed mice underwent oral and 
intraperitoneal (IP) glucose tolerance tests (GTTs) 2 and 3 weeks after LPS, 
respectively. On the day of both the oral GTT (mean±SEM; Chow-Veh 31.91g±0.45; 
Chow-LPS 30.46g±0.53; HFD-Veh 48.43g±1.19; HFD-LPS 46.59g±1.23) and IP GTT 
(mean±SEM; Chow-Veh 31.11g±0.29; Chow-LPS 30.09g±0.67; HFD-Veh 49.58g±1.17; 
HFD-LPS 48.43g±1.06) the body weight of LPS vs. Veh-treated mice were not different. 
LPS had no significant impact on oral glucose tolerance (Figure 3.9A) in chow- or HFD-
fed mice. However, while HFD-fed mice had significantly greater glucose responses 
compared to chow fed mice, both LPS treated groups had impaired IP glucose 
tolerance, regardless of diet (Time x Diet p<0.0001, Time x Treatment p=0.0049) 
(Figure 3.9B). Together these data suggest that LPS treatment has a lasting impact on 




Type 2 diabetes mellitus (T2DM) remains a pervasive problem both in the United States 
and around the world (275). The COVID-19 pandemic was a prime example of how 
T2DM and the associated immune dysfunction can adversely impact the immune 
responses (278). I found that high-fat diet (HFD) increases physiological responses to 
severe inflammation including greater increases in total GLP-1, greater sickness-
induced anorexia and dysregulated energy homeostasis, and that GLP-1 directly 
regulates macrophage accumulation in response to LPS. Thus, GLP-1 plays an 
immunologic, rather than metabolic, role in response to LPS.  
GLP-1 is traditionally thought of as an incretin hormone which increases after a meal 
and functions to insulin secretion and thus control blood glucose levels (37,38,42,43). 
Many studies have investigated the GLP-1 response to inflammation (139,143,285,286). 
Under severe inflammatory conditions, such as sepsis, patients have remarkably 
increased GLP-1 levels and this increase is associated with higher mortality rates (300).  
As stated above, I used LPS as an inflammatory stimulus which results in a strong, 
systemic inflammatory response including increased systemic cytokine production and 
decreased food intake (296,297). In my HFD vs. chow-fed experiments I saw that HFD-
fed mice had a stronger physiological response to the LPS. I found that HFD mice had 
increased plasma GLP-1 two hours after LPS administration. This greater increase in 
GLP-1 is consistent with what is seen in human T2DM data who have had sepsis 
(152,295,300). In addition, the HFD-fed mice had increased sickness-induced anorexia 
as seen by the food intake data and increased cytokine production. Together, these 
data show that HFD increases the inflammatory state after LPS, including plasma GLP-
1 levels suggesting that GLP-1 is involved in the immune response. Indeed, researchers 
have shown that GPL-1 levels predict mortality of patients with critical illness (300).    
The function of endogenous GLP-1 under inflammatory conditions remains unknown. 
Because LPS is a known anorectic agent that alters glucose homeostasis, both 
functions of GLP-1, I predicted that the role of GLP-1 in response to LPS would be an 
extension of its postprandial functions. While pancreatic GLP-1 contributed relatively 
more GLP-1 to the circulation, neither the pancreatic nor intestinal sources of GLP-1 
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were necessary for the anorectic or glucose responses to LPS. Together these data 
imply that the function of GLP-1 under inflammatory conditions differs from its function 
postprandially. This is corroborated by my insulin data which shows no increase in 
plasma insulin despite increased circulating GLP-1 levels after LPS administration.  
Because obesity and T2DM impact GLP-1 levels, in a separate cohort of mice fed HFD, 
I investigated these same endpoints. In these experiments, only the control mice had a 
significant increase in total GLP-1. This lack of increase in the GcgRAΔPanc mice could 
be due to baseline increases of GLP-1 in the HFD-fed mice, or that the HFD 
GcgRAΔPanc mice have dysregulated responses to diet and/or LPS due to lack of Gcg in 
either the gut or hindbrain.  
GLP-1 agonists have been implicated in anti-inflammatory signaling in multiple tissues 
(153,287,288,301). Exendin-4 (Ex-4) has been show to decrease circulatory cytokine 
levels after both LPS and Ex-4 administration (153). Similarly, patients administered 
liraglutide over six weeks had decreased cytokine levels measured in mononuclear cells 
(287). Additionally, GLP-1 agonists increased functional recovery and viability of 
cardiomyocytes with and without GLP-1R (302). Despite well-established anti-
inflammatory effects of GLP-1, how GLP-1 agonists contribute to an anti-inflammatory 
state remains unknown. Furthermore, whether endogenous GLP-1 has the same effect 
as long-acting GLP-1 agonists in unknown. In the above experiments, I did not observe 
any difference in systemic cytokine levels between Gcg Null, GcgRAΔPanc, GcgRAΔInt vs. 
control mice, regardless of diet. The discrepancy between the effects of endogenous 
GLP-1 and exogenous administration of long-lasting GLP-1 agonists could be explained 
by the rapid degradation of GLP-1 in circulation (155–157). While long-lasting agonists 
have systemic anti-inflammatory properties, perhaps endogenous GLP-1 has a local 
effect in GLP-1 producing tissues, the intestine and pancreas. As mentioned above, 
under LPS induced inflammation there is an increase in pancreatic produced GLP-1 in 
chow-fed mice. This is different from what is seen postprandially, where the 
predominant source of GLP-1 is from the intestine (33). Given this more novel source of 
GLP-1, I wanted to investigate specifically the impact of Gcg- derived peptides on 
pancreatic inflammation. The flow cytometry data comparing Gcg Null versus control 
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mice shows that after LPS, the Gcg Null-LPS group had significantly more 
CD64+CD11b+ cells compared to all other groups. This population was of interest to me 
because under HFD-induced chronic inflammation, this subpopulation of macrophages 
are the major contributor to the immune environment of the islet (259). I saw similar 
results in both the chow fed and HFD-fed mice. However, it is important to note that the 
HFD mice had a greater number of unhealthy cells leaving the populations of 
macrophages less distinct in the HFD flow analysis and this effect was greater in Gcg 
Null vs. control mice. This implies that the absence of Gcg increases the inflammatory 
state of the pancreas.  
The strength of flow cytometry is that it allows both the characterization and 
quantification of the macrophages, but not the localization. To look at the anatomical 
accumulation of the immune cells, I quantified percentage of area positive for F4/80 
staining compared to the total, islet, and acinar area. In both chow and HFD-fed mice, 
there was an increase in F4/80 staining in response to LPS, but this increase was 
similar in control, Gcg Null, and GcgRAΔPanc mice. While I had a validated F4/80 
antibody and protocol available for the IHC samples, I used both F4/80 and CD64 
antibodies for the flow experiment. The CD64 population was more distinct so I used it 
to distinguish the macrophages along with CD11b rather than F4/80. Both F4/80 and 
CD64 are common macrophage markers (303,304). However, while flow cytometry 
revealed a significant increase in macrophages in the pancreas in in the Gcg Null mice 
in response to LPS, I saw no significant genotype effect with IHC. This difference can 
be explained by the fact that the flow experiment used the entire pancreas is isolate 
macrophages, whereas the IHC images were taken of the islets and the surrounding 
tissue. Images taken only around the islet might skew the results for the acinar 
population. Despite this discrepancy, these data imply that macrophages accumulate in 
the pancreas after an inflammatory insult, and Gcg Null mice have increased 
CD64+CD11b+ macrophages compared to control mice.  
As discussed above, GLP-1 agonists result in anti-inflammatory signals 
(153,287,288,301,302). However, it is unclear how GLP-1 agonists are contributing to 
the anti-inflammatory state. Is it through CNS or peripheral signaling, or via direct 
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regulation of immune cells? To determine whether GLP-1 could directly regulate 
macrophages I used a Glp1r-GFP reporter mouse. It is well established that there are 
few, perhaps just one, antibody that is sensitive and accurate enough to detect the 
GLP-1R. To avoid this issue, I used a GLP-1RΔCre mouse crossed to an eGFP-L10 
reporter line and used flow cytometry to gate for GFP and immune cells. I found that a 
population of CD64+ CD11b+ cells were also positive for GFP in the pancreas implying 
that there are macrophages within the pancreas that express GLP-1R. However, there 
were no cell population that was positive for both immune cell markers and GFP. Thus, I 
hypothesize that GLP-1 directly regulates macrophage accumulation in the pancreas. 
This conflicts with a recent study which looked at the impact of liraglutide on bone 
marrow macrophages and found GLP-1R expression in both these macrophages and 
RAW264.7 cells, a macrophage cell line (305). However, single cell transcriptome 
analysis found GLP-1R expression in both classical monocytes, a macrophage 
precursor, and natural killer cells, an important cell type in innate immune responses, in 
the lung (306). This is an entirely new role for GLP-1 and puts forth a new hypothesis of 
why GLP-1 agonists show anti-inflammatory properties. 
One limitation of this study is the specificity of the PDX1-Cre expression in our promotor 
mouse. PDX1-Cre is expressed in both the pancreas and duodenum. Previous research 
has shown that the predominant source of GLP-1 postprandially is the ileum and colon 
(33), so the PDX1-Cre promoter is still useful as a pancreatic promoter for Gcg.  
Additionally, our Cre model targets the entire Gcg gene and all the peptides it encodes. 
Indeed, glucagon is an important counterregulatory hormone that may play a role in the 
local inflammatory state of the islet and cannot be discounted at this time. Although 
tools are limited at this time, future studies targeting either GLP-1 and/or glucagon could 
offer further insight into pancreatic Gcg peptides and local inflammatory responses.  
This study puts forth an additional role for GLP-1, as a macrophage regulating peptide. 
LPS-induced inflammation resulted in impaired glucose tolerance 3 weeks later. 
Previous data has shown that islet macrophage accumulation impacts glucose-
stimulated insulin secretion (259). Together, these data show the lasting effect of 
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inflammation on islets and could be particularly impactful for pre-diabetic patients who 
have an inflammatory insult as it could exacerbate the progression to T2DM.  
Conclusion 
These experiments explored the interaction between LPS-induced inflammation and 
metabolism and found that HFD-fed mice had increased susceptibility to the symptoms 
of LPS-induced inflammation. It also put forth a novel function of GLP-1 as a direct 
regulator of macrophage accumulation. 
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Figure 3.1 Impact of LPS on plasma GLP-1 in HFD versus chow-fed mice. LPS was either dosed per body weight 
(100ng/g) or as a flat dose (0.32ug) and (A, C) glucose, and (B, D) plasma total GLP-1 were measured, respectively. 
HFD-fed mice had a greater fall from baseline glucose at 4 hours and a greater increase in total GLP-1 at 2 hours 
regardless of dosage. Data in this figure were statistically analyzed with a 2-way (or mixed model) (A-B) or 3-way (C-
D) ANOVA with Tukey post hoc analysis when appropriate, each animal was tested once, and data are represented 

















Figure 3.2 HFD-fed mice have a prolonged anorectic effect in response to LPS compared to chow-fed mice. 
Mice (n=6/group) were acclimated to the metabolic chambers for two days. (A) Mice were matched for body weight. 
(B) Total body weight, (C) lean mass, (D) and fat mass loss 3 days after LPS (4ug). (E) The HFD-LPS group has 
decreased food intake compared to the Chow-LPS group. (F) Cumulative food intake during recovery from LPS (Day 
2 and 3). (G) Energy expenditure in chow and HFD groups the 3 days following treatment with Veh or LPS. (H) 
Average energy expenditure separated into dark and light cycles over the three-day experiment; the Chow-LPS mice 
had significantly lower energy expenditure during the dark cycle of Day 1 compared to the Chow-Veh group. (I) RER 
for all groups over 3 experiment days in response to Veh vs. LPS. (J) The average RER for Day 1 was significantly 
higher in the Chow-Veh group compared to all others, and on Days 2 and 3 both chow groups were significantly 
higher compared to the HFD-fed groups. Data in this figure were statistically analyzed with a 2-way (A-D), or a 3-way 
(H-J) ANOVA with Tukey post hoc analysis when appropriate, or an unpaired t-test (E-F inset graphs), each animal 







Figure 3.3 HFD-fed mice have increased inflammatory responses to LPS compared to chow-fed mice. 
Following vascular catheterization, mice (Chow-Veh, n=6; Chow-LPS, n=9; HFD-Veh, n=8; HFD-LPS, n=8) recovered 
for 3-5 days and were administered LPS (4ug) via the jugular vein and (A) glucose, (B) total GLP-1, (C) insulin, (D) 
glucagon, (E) IL-6, (F) TNF-α and (G) IL-1β were measured. LPS treated mice had decreased glucose levels over 
time (Time x Treatment p<0.0001). Total GLP-1 (Time x Treatment p<0.0001) and glucagon (Time x Treatment 
p<0.0001) were increased over time in LPS-treated groups. Insulin levels were increased by diet but were not 
significantly impacted by LPS treatment. The iAUC for IL-6 and TNF-α were increased in HFD compared to chow-fed 
mice. There was no significant difference between dietary groups in the LPS-induced increase in IL-1β. Following the 
experiment, liver tissue was collected for cytokine and chemokine expression including (H) IL-6, (I) TNF-α, (J) IL-10 
and (K) MCP-1. While there was a clear impact of LPS on liver cytokine production, there was no significant 
additional impact of HFD. Data in this figure were statistically analyzed with a 3-way (A-G) ANOVA with Tukey post 
hoc analysis when appropriate or 2-way (H-K) ANOVA with Tukey post hoc analysis when appropriate, each animal 











Figure 3.4 The role of Gcg in the physiological responses to LPS in chow-fed mice A brief schematic of the (A) 
Gcg genetic models are shown. Following a 4 hour fast, mice (Con-Veh, n=15; Con-LPS, n=13; Gcg Null-Veh, n=14; 
Gcg Null-LPS, n=14; GcgRAΔPanc-Veh, n=6; GcgRAΔPanc-LPS, n=8; GcgRAΔInt-Veh, n=7; GcgRAΔInt-LPS, n=7) were 
administered LPS (100ng/g) via an IP injection and food intake (B) was measured. (C) Food intake expressed as % 
difference from saline was similar between genotypes. A separate cohort of mice (Con-Veh, n=13; Con-LPS, n=14; 
Gcg Null-Veh, n=13; Gcg Null-LPS, n=14; GcgRAΔPanc-Veh, n=7; GcgRAΔPanc-LPS, n=8; GcgRAΔInt-Veh, n=9; 
GcgRAΔInt-LPS, n=10) were administered LPS as in (B) for panels D-K.  (D) There was no significant change in 
glucose in response to saline over time or between genotypes. (E) There was a drop in glucose over time in response 
to LPS but no significant difference between genotypes. (F) At 240 minutes after LPS, total GLP-1 was increased in 
the Con and GcgRAΔPanc mice. (G) There was no significant increase in insulin detected in response to LPS. (H) 
Glucagon was significantly higher in response to LPS in Con and GcgRAΔPanc mice and undetectable in both the Gcg 
Null and GcgRAΔInt mice. (I) Plasma IL-6 response to LPS (Veh levels indicated by dashed line) was significantly 
higher in the GcgRAΔPanc group. (J-K) There were no detectable difference between genotypes for TNF-α and IL-1β 
plasma levels after LPS (Veh levels indicated by dashed line).  Hepatic expression of (Con-Veh, n=5; Con-LPS, n=8; 
Gcg Null-Veh, n=4; Gcg Null-LPS, n=7; GcgRAΔPanc-Veh, n=6; GcgRAΔPanc-LPS, n=8) both IL-6 (L) and TNF-α (M) 
were significantly increased in response to LPS but there was no impact of genotype. Data in this figure were 
statistically analyzed with a 3-way (B, D-E) ANOVA with Tukey post hoc analysis when appropriate or 2-way (C, F-M) 
ANOVA with Tukey post hoc analysis when appropriate, each animal was tested once, and are represented as Mean 




Figure 3.5 The role of Gcg in the physiological responses to LPS in HFD-fed mice Following a 4 hour fast, mice 
(n=7/group) were administered LPS (100ng/g) via an IP injection and food intake (A) was measured. (B) Food intake 
expressed as % difference from saline was not significantly different between genotypes. In a separate cohort of mice 
(Con-Veh, n=14; Con-LPS, n=20; Gcg Null-Veh, n=14; Gcg Null-LPS, n=16; GcgRAΔPanc-Veh, n=8; GcgRAΔPanc-LPS, 
n=9; GcgRAΔInt-Veh, n=7; GcgRAΔInt-LPS, n=8) were administered LPS as in (A) for panels C-J. (C) There was no 
significant change in glucose in response to saline over time or between genotypes. (D) There was a drop in glucose 
over time in response to LPS but no significant difference between genotypes. Blood was collected at 240 minutes 
and (F) plasma total GLP-1, (G) plasma Insulin, (H) plasma glucagon, (I) plasma IL-6, (J) plasma TNF-α, (K) plasma 
IL-1β were measured. All groups, regardless of genotype, responded similarly to LPS (Veh levels indicated by 
dashed line). Hepatic expression of (L) IL-6 and (M) TNFα were increased in response to LPS, but there was no 
significant impact of genotype on these responses (Con-Veh, n=7; Con-LPS, n=9; Gcg Null-Veh, n=6; Gcg Null-LPS, 
n=6; GcgRAΔPanc-Veh, n=8; GcgRAΔPanc-LPS, n=9. Data in this figure were statistically analyzed with a 3-way (A, C-D) 
ANOVA with Tukey post hoc analysis when appropriate or 2-way (B, H-L) ANOVA with Tukey post hoc analysis when 




Figure 3.6 Gcg Null mice have increased macrophage accumulation in the pancreas after LPS 24h after LPS, 
mouse (n=4/group) pancreata cells were (A) gated on singlets, scatter, and CD45+ cells. The population of interest, 
CD64+CD11b+ was quantified and analyzed. Gcg Null-LPS mice have increased macrophage accumulation 
compared to all other groups. In a separate cohort (Con-Veh, n=4; Con-LPS, n=4; Gcg Null-Veh, n=3; Gcg Null-LPS, 
n=3; GcgRAΔPanc-Veh, n=4; GcgRAΔPanc-LPS, n=4; GcgRAΔInt-Veh, n=4; GcgRAΔInt-LPS, n=4) pancreas sections were 
stained for (B) F4/80 using DAB and (C-E) quantified. LPS-treated mice had increased macrophage accumulation in 
the (C) total pancreas (p<0.0001), including both the (D) islet (p=0.0117), and (E) acinar cells (p<0.0001) regardless 
of genotype.  Data in this figure were statistically analyzed with a 2-way (A, C-E) ANOVA with Tukey post hoc 




























Figure 3.7 Gcg Null mice fed HFD also have increased macrophage accumulation in the pancreas after LPS 
Mice (Con-Veh, n=4; Cre-LPS, n=4; Gcg Null-Veh, n=3; Gcg Null-LPS, n=3) pancreata was stained for immune cells 
and acquired on a flow cytometer. The cells were (A) gated on singlets, scatter and CD45+ cells. LPS mice have 
increased CD64+CD11b+ accumulation compared to veh groups (Treatment p=0.0297) and macrophages were 
higher in Gcg Null mice (Genotype p=0.0369). In a separate cohort HFD-fed mice pancreata were collected 24 hours 
after LPS and sections were stained for (B-E) F4/80 using DAB. LPS-treated mice had increased macrophage 
accumulation in the (C) total pancreas (p=0.0395), but not the (D) islets, implying increase was in the (E) acinar cells 
(p=0.0245). This was consistent across genotypes.  Data in this figure were statistically analyzed with a 2-way (A, C-
E) ANOVA with Tukey post hoc analysis when appropriate, each animal was tested once, and are represented as 
Mean ± SEM.  
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Figure 3.8 Macrophages isolated from the pancreas express GLP-1R. A brief schematic of the (A) Glp1r-GFP 
reporter mouse is shown. 24 hours after LPS (100ng/g) administration, immune cells were isolated from pancreata 
and bone marrow (Wild-type n=1, Glp1r-GFP-LPS n=2), stained, and acquired on the flow cytometer using the gating 
scheme (B) shown. Wild-type mice showed no GFP signal (C), whereas Glp1r-GFP mice showed a strong GFP 











Figure 3.9 HFD-fed mice have impaired IP glucose tolerance 3 weeks after LPS Mice (n=6/group) administered 
LPS (0.32ug) had no significant difference in (A) oral glucose tolerance (oGTT) compared to saline-treated mice, 
regardless of diet. (B) Both HFD and LPS treatment impaired IP glucose tolerance but there was no significant 
interaction of diet and treatment (Time x Diet p<0.0001, Time x Treatment p=0.0049). Data in this figure were 






















Supplementary Figure 3.1 Energy Expenditure response to LPS is similar when expressed relative to body 
weight (A) Energy expenditure expressed relative to body weight was decreased in the Chow-LPS group, but not in 
the HFD-LPS group. (B) The average energy expenditure did not have a significant 3-way interaction but there was a 
significant Day x Treatment interaction (p<0.0001) and a main effect of diet (p=0.0441). Data in this figure were 
statistically analyzed with a 3-way ANOVA (B) with Tukey post hoc analysis, each animal was tested once, and data 













CHAPTER 4                                                                                                                 
Conclusion 
Significance of Findings 
Type 2 diabetes mellitus (T2DM) remains a pervasive problem around the world 
(276,277). The COVID-19 pandemic was a startling example of the how dysfunction of 
the adaptive and innate immune systems with T2DM impacts mortality from 
inflammatory insults (278). It is critical moving forward that we understand how the 
pathophysiology of T2DM impacts immune responses. This knowledge will help to both 
decrease mortality rates of T2DM patients under severe inflammatory conditions as well 
as innovate new therapeutics. This dissertation made important strides towards 
understanding the local inflammatory state of the pancreas with endotoxemia, the 
factors that regulate it, as well as the impact of diet-induced obesity on these 
responses. Recently, researchers have been investigating the impact of GLP-1 and 
specifically, GLP-1R agonists, on responses to inflammation (139,143,285,286). Under 
severe inflammatory conditions, such as sepsis, patients have remarkably increased 
GLP-1 levels and this increase is associated with higher mortality rates (300). However, 
the function of GLP-1 under inflammatory conditions remains unknown. This 
dissertation puts forth an additional role for GLP-1, as a macrophage regulating peptide 
directly through its receptor, GLP-1R.  
First, I found that HFD increases total GLP-1 (Figure 3.1) responses to severe 
inflammation, which is consistent with human data in the literature (300). This led me to 
wonder about symptoms associated with severe inflammation that could be impacted by 
GLP-1 such as glucose levels and appetite. I found that under HFD conditions, mice 
had greater sickness-induced anorexia and dysregulated energy homeostasis (Figure 
3.2) compared to chow-fed mice. Using our innovative Gcg tissue-specific reactivation 
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mouse model, I found that GLP-1 plays an immunologic, rather than a metabolic role 
(Figure 3.3-3.7). Specifically, glucose and insulin levels were not impacted by Gcg, and 
instead, availability of Gcg prevents excessive macrophage accumulation in the 
pancreas. This is significant because it is a new role for GLP-1 which is traditionally 
described as an incretin (37,38,42,43). Furthermore, using a Glp1r reporter mouse, I 
found evidence that GLP-1R was expressed on pancreatic macrophages (Figure 3.8), 
implying that GLP-1 directly regulates macrophages.  
Last, I found that LPS-induced inflammation resulted in impaired glucose tolerance 
(Figure 3.9B) even after the mice had three weeks to recover. Importantly, this was 
only seen in the intraperitoneal (IP) glucose tolerance test (GTT) whereas the oral GTT 
(oGTT) was not impacted by LPS. A possible explanation for this is that the incretin 
activation from the gut after oral administration helps to better control glucose levels 
after a severe inflammatory insult. This important experiment shows the potential 
damage to pancreatic and gut function after a severe inflammation. In animal studies, 
HFD results in accumulation of macrophages in the pancreas and is associated with 
impaired glucose stimulated insulin secretion (259). The above data suggest that the 
pancreatic accumulation of macrophages that occurs after LPS leads to long-lasting 
impairments in glucose tolerance. Together, these data indicate a need for better 
understanding how inflammation impacts pancreatic function, and whether endogenous 
GLP-1 or GLP-1R agonists are protective against tissue damage due to inflammation.  
Strengths & Limitations 
This study utilized several innovative mouse models. First, our Gcg reactivation model 
allowed me to distinguish the impact of tissue-specific production (Figure 3.4-3.8) of 
Gcg-derived peptides, rather than using a knockout model. This is especially important 
for my experiments because I wanted to investigate the impact of Gcg-derived peptides 
on both the systemic and local inflammatory responses; Gcg is produced in multiple 
tissues and each source of Gcg has been implicated in energy and glucose regulation. 
In addition to inflammatory endpoints, this model allowed me to distinguish any potential 
glucoregulatory differences between intestinal and pancreatic GLP-1, which are 
reported for post-prandial GLP-1 (37,38,42,43). 
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However, our Cre model targets the entire Gcg gene and all the peptides it encodes. 
Indeed, glucagon is an important counterregulatory hormone that may play a role in the 
local inflammatory state of the islet and cannot be discounted. Although tools are limited 
to create this mouse model now, future studies targeting either GLP-1 and/or glucagon 
could offer further insight into pancreatic Gcg peptides and local macrophage responses. 
Specifically, GLP-2, another Gcg-derived peptide, has also been reported to have anti-
inflammatory properties (307,308).   
Another potential problem with our PDX1-Cre mouse model is the specificity of the 
PDX1-Cre expression in our promotor mouse. PDX1-Cre is expressed in both the 
pancreas and duodenum. Previous research has shown that the predominant source of 
GLP-1 postprandially is the ileum and colon (33), so the PDX1-Cre promoter is still 
useful as a pancreatic promoter for Gcg.  Future studies could use an AAV-Cre based 
virus administered directly through the pancreatic duct to specifically target the 
pancreas.  
Whether GLP-1R are expressed on macrophages, and other immune cells for that 
matter, is unknown as GLP-1R antibodies are questionable (299). To address this 
problem, I used a mouse model which crossed an eGFP-L10a reporter mouse to a 
Glp1rΔCre (Figure 3.8A) mouse, generously provided by Dr. D. Olson. I was able to 
detect immune cells that are also positive for GLP-1R without the weaknesses 
associated with the available GLP-1R antibodies. This finding that GLP-1R are located 
in pancreatic, but not bone marrow-derived macrophages suggests that, at least this 
specific population of macrophages that respond to LPS, are resident macrophages. An 
alternative explanation is that the circulating macrophages may change their genotype 
once they start accumulating in the pancreas. Macrophages are very plastic cells (309) 
and thus, this explanation is a distinct possibility. These data provide an increasing 
amount of rationale for the idea that GLP-1 directly regulates the immune response to 
inflammatory stress in the pancreas.  
I also used an innovative combination of IHC and flow cytometry (Figure 3.6-3.7) to 
look at the accumulation and characterization of macrophages in the mouse pancreas. 
To look at the accumulation of the immune cells, I quantified percentage of area positive 
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for F4/80 staining (Figure 3.6C-E, Figure 3.7C-E). In both chow and HFD-fed mice, 
there was an increase in F4/80 staining in response to LPS. While I had a validated 
F4/80 antibody and protocol available for the IHC samples, I used both F4/80 and CD64 
antibodies for pilot flow experiments as I was establishing a panel that could be properly 
compensated. The CD64 population was more distinct so I used it to distinguish the 
macrophages along with CD11b rather than F4/80. Both F4/80 and CD64 are common 
macrophage markers (303,304). However, I saw a statistically different response in the 
Gcg Null-LPS mice in the flow experiment, indicated by CD64, but not with the IHC 
strategy using F4/80 staining. It is possible that the different antibodies contributed to 
the lack of ability to detect an impact of genotype with IHC. However, I believe a more 
likely issue is that the I used the whole pancreas for the flow cytometry experiment, 
whereas the IHC images were taken of islets and the surrounding cells. Images taken 
only around the islet might skew the results; future studies could analyze the entire slide 
rather than focus on the islets. I also used DAB staining, counterstained with 
hematoxylin, and quantified as area stained rather than by individual nuclei. It is 
possible that my quantification strategy would be improved with the use of fluorescent 
antibodies and DAPI instead to quantify by nuclei. A method that I piloted to understand 
better the islet inflammatory state, was to isolate islets from Gcg Null vs. control mice 24 
after LPS administration. Unfortunately, the combination of Gcg Null and LPS resulted 
in very unhealthy islets even with an overnight incubation recovery which is standard 
procedure. In this flow experiment, there was too much debris and too little immune 
cells to identify populations.  
Because my chow-fed vs. HFD mouse metabolic experiments were limited by time 
points that could be taken via tail nick and blood volume, I designed a study to examine 
the time course responses of plasma levels of metabolic hormones and cytokines in 
response to LPS. Mice had catheters placed in the carotid artery and jugular vein in 
order to minimize handling of the mice. Additionally, this method allowed me to draw 
larger (about 200 μL), and more frequent blood draws (five blood draws throughout the 
experiment).  I was able to do this with the aid of heparin washed red blood cells from 
donor mice which were administered via the jugular vein throughout the three-hour 
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experiment. While this experiment was technically difficult to learn, it was a valuable 
experience and yielded important findings for my dissertation.   
Public Health Relevance 
As discussed above, under severe inflammatory conditions, such as sepsis, patients 
have remarkably increased GLP-1 levels and this increase is associated with higher 
mortality rates (300). Recent research has shown that macrophages accumulate within 
the islet during diet-induced obesity leading to elevated levels of pro-inflammatory 
cytokines (259). Similarly, recent work demonstrates that during obesity, islet-resident 
macrophages proliferate contributing to a local inflammatory state and this results in 
impaired β-cell function (259,283). Collectively, these data indicate growing evidence 
that pancreatic inflammation/macrophage accumulation occurs with obesity, and this 
contributes to impaired β-cell function and thus could be a critical contributing factor in 
the progression of T2DM. The impact of COVID-19 on islet function supports the 
importance of studying pancreatic inflammatory responses (284).  
I found that a population of CD64+ CD11b+ macrophage cells that were also positive for 
the GLP-1R in the pancreas (Figure 3.8C) implying that there are macrophages within 
the pancreas that express GLP-1R. Thus, GLP-1 could directly regulate macrophage 
signaling in the pancreas. Single cell transcriptome analysis found GLP-1R expression 
in classical monocytes and natural killer cells in the lung (306) indicating that the 
pancreas may not be the only organ where GLP-1R are regulating macrophage 
accumulation. Together, these data provide an increasing amount of rationale for GLP-1 
to be directly regulating macrophages. This is an entirely new role for GLP-1 and puts 
forth a new hypothesis of why GLP-1R agonists show anti-inflammatory properties.  
The development of GLP-1-based drugs has been a major advance in T2DM 
management. The approved pharmaceutical strategies targeting the GLP-1 system 
either increase endogenous GLP-1 levels with DPP4 inhibitors, or are long-acting GLP-
1R agonists resistant to DPP4 cleavage (228,229). DPP4 inhibitors are effective at 
stimulating insulin and reducing glucagon, attributes that are credited to GLP-1R 
signaling (230). One of the most used GLP-1R agonists has an extended circulatory 
half-life is accomplished by the addition of a fatty acid side chain to native GLP-1 which 
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facilitates albumin binding (Liraglutide/Victoza). Besides being more convenient for the 
patient, liraglutide treatment also results in a reduction in cardiovascular events (242). 
The reduction of cardiovascular events is interesting because GLP-1R agonists have 
been implicated in anti-inflammatory signaling in multiple tissues including 
cardiomyocytes (153,287,288,301). Exendin-4 (Ex-4), a GLP-1R agonist, has been 
shown to decrease circulatory cytokine levels after LPS administration (153). Similarly, 
patients administered liraglutide had decreased cytokine levels measured in 
mononuclear cells after six weeks of administration (287). A recent paper showed that 
COVID-19 patients who remained on sitagliptin, a DPP4 inhibitor, while in the ICU had 
increased survival compared to patients treated with standard of care, stopping 
sitagliptin and treating with insulin (310). Despite the established anti-inflammatory 
effects of GLP-1R agonists, how the agonists contribute to an anti-inflammatory state 
remains unknown. Furthermore, whether endogenous GLP-1 has the same effect as 
long-acting GLP-1R agonists in unknown. In the above experiments, I did not observe 
any difference in systemic cytokine levels (Figure 3.4I-M, Figure 3.5H-L) between Gcg 
Null, GcgRAΔPanc, GcgRAΔInt vs. control mice, regardless of diet. The discrepancy 
between the effects of endogenous GLP-1 and exogenous administration of long-lasting 
GLP-1R agonists could be explained by the rapid degradation of GLP-1 in circulation 
(155–157). While long-lasting agonists have systemic anti-inflammatory properties, 
perhaps endogenous GLP-1 has a local effect in GLP-1 producing tissues, the intestine, 
pancreas, and CNS. 
As mentioned above, LPS-induced inflammation resulted in impaired glucose tolerance 
(Figure 3.9B) after the mice had three weeks to recover. These data show the lasting 
effect of inflammation on islets and could be particularly impactful for pre-diabetic 
patients who have an inflammatory insult as it could exacerbate the progression to 
T2DM. 
Future Studies & Applications 
There are many hypotheses that could come from this dissertation regarding GLP-1 
expression and receptor signaling, as well as immune cell function. Here I put forth two 
future studies that are important follow up to the data in this dissertation.  
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First, in recent years, it has become increasingly evident that too much research is done 
in male mice only. This dissertation is in fact, guilty of this. While male mice are an 
important control, it is vital to establish how female physiology is the same or different in 
the groundbreaking research happening around the world. Specific to this dissertation, 
sex differences in GLP-1 expression (311) and immune system responses (312) have 
been detected. An interesting endpoint that I did repeat in female mice was assessing 
glucose tolerance after LPS. In the female mice, there was no impact of LPS treatment 
on either oral or IP glucose tolerance (Figure 4.1). This indicates that female mice might 
be protected from the impaired pancreatic function after LPS. Digging into this 
phenomenon further with female Gcg reactivated mice could yield data on sex differences 
in the immune response of the pancreas.  
As mentioned above, one of the interesting outcomes from this dissertation was the 
observation that LPS-treated mice had impaired glucose tolerance, at least in male mice. 
Future studies could explore pancreatic damage and recovery after severe inflammation. 
Both endocrine and exocrine function could be impacted.  
Finally, the Gcg Null, GcgRAΔPanc and GcgRAΔInt mice used in these experiments are 
lacking Gcg expression in the hindbrain. While it is known that glutamatergic rather than 
GABAergic neurons (98) are necessary for liraglutide to induce weight loss, whether 
these neurons are also necessary for or impact any of the physiological responses to 
LPS is unknown.  
Conclusion 
The data from this dissertation significantly advances our understanding of the function 
of the increase in pancreatic GLP-1 production with inflammatory stress. Furthermore, it 
explores the impact of HFD on immune responses, including Gcg. I found that HFD 
exaggerates physiological responses to LPS including increased GLP-1, decreased 
blood glucose, and a greater anorectic effect. I also found that Gcg-derived peptides play 
a role in pancreatic macrophage accumulation in response to inflammation. Finally, I 
found that macrophages isolated from the pancreas express GLP-1R indicating that GLP-
1 could be directly signaling macrophages and regulating local inflammation.  
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Figure 4.1: Female mice do not have impaired glucose tolerance in response to LPS regardless of diet Mice 
(n=6/group) administered LPS (0.32ug) had no significant difference in (A) oral glucose tolerance (oGTT) compared 
to saline-treated mice, however there was a significant interaction of diet (Time x Diet p=0.0029). (B) Only HFD 
impaired IP glucose tolerance but there was no significant interaction of diet and treatment (Time x Diet p<0.0001). 
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